Article

Subscriber access provided by CORNELL UNIVERSITY LIBRARY

Microwave-assisted organocatalytic intramolecular Knoevenagel/ hetero Diels-Alder reaction with O-(arylpropynyloxy)salicylaldehydes. Synthesis of polycyclic embelin derivatives.

Pedro Martín-Acosta, Gabriela Feresin, Alejandro Tapia, and Ana Estevez-Braun

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.6b01818 • Publication Date (Web): 28 Sep 2016 Downloaded from http://pubs.acs.org on September 30, 2016

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.


Microwave-assisted organocatalytic intramolecular Knoevenagel/ hetero Diels-Alder reaction with *O*-(arylpropynyloxy)salicylaldehydes. Synthesis of polycyclic embelin derivatives.

Pedro Martín-Acosta,[†] Gabriela Feresin, [‡] Alejandro Tapia, [‡] Ana Estévez-Braun*,[†]

[†]Instituto Universitario de Bio-Orgánica Antonio González (CIBICAN), Departamento de Química Orgánica, Universidad de La Laguna, Avda. Astrofísico Francisco Sánchez Nº 2, 38206, La Laguna, Tenerife, Spain

* E-mail: aestebra@ull.es

[‡] Instituto de Biotecnología-Instituto de Ciencias Básicas, Universidad Nacional de San Juan, Av. Libertador General San Martín 1109 (O), CP 5400, San Juan, Argentina



A highly efficient and regioselective approach to new polycyclic embelin derivatives through a domino Knoevenagel condensation /intramolecular hetero Diels-Alder reaction using *O*-(arylpropynyloxy)-salicylaldehydes in the presence of ethylenediamine diacetate (EDDA) is reported. This organocatalyzed protocol is compatible toward a wide range of aryl-substituted alkynyl ethers with electrondonating and electron-withdrawing groups. When other active methylene compounds were subjected to this domino reaction the corresponding adducts were obtained in high yield.

Introduction

Natural products scaffolds have been well recognised as "privileged structures" in terms of their ability to be the basis for successful drugs.¹ An assessment of all FDAapproved new molecular entities (NMEs) reveals that natural products and their derivatives represent over one-third of all NMEs.² Such scaffolds can be used as cores of compound libraries. As a privileged scaffold, the benzoquinone core is ubiquitous in many bioactive natural products and pharmaceuticals.³ Understandably, particular emphasis has been put on the development of methodologies for its synthesis, with an aim to develop facile and efficient protocols to provide benzoquinone and benzoquinone-based compound libraries.⁴

Embelin (1) is a naturally occurring alkyl substituted hydroxybenzoquinone and a major constituent of the Andean medicinal plant *Oxalis erythrorhiza Gillies ex Hook* & *Arn*, belonging to the Oxalidaceae family.⁵

It has been reported that embelin possess antidepressant,⁶ antitumor,⁷ antiinflammatory,⁸ analgesic,⁹ antioxidant,¹⁰ antidiabetic,¹¹ wound healing,¹² and antibacterial properties.¹³ All these activities make embelin a "promiscuous compound"¹⁴ due specific interactions with multiple targets such as 5-lipoxygenase,¹⁵ the stress chaperone mortalin,¹⁶ XIAPs,¹⁷ NFκB,¹⁸ STAT-3,¹⁹ Akt²⁰ and mTOR,²¹ and consequently an interesting scaffold for synthesizing new and more selective therapeutic agents.

Since that increased molecular complexity in natural products and diverse compounds, is associated with improved selectivity and frequency of binding,²² the development of libraries of complex compounds with balanced physicochemical properties could led to obtain compounds having efficient binding with specific

biological targets.²³ In this sense, the use of domino reactions is a good synthetic strategy for the construction of complex polycyclic scaffolds.²⁴

In recent years the domino-Knoevenagel-hetero-Diels-Alder reaction, developed by Tietze's group, has emerged as a powerful process that not only allows the efficient synthesis of complex compounds but also permits the preparation of highly diverse molecules, specially pyran and pyrano-fused carbocycles. These pyran and pyranofused ring systems represent important molecular frameworks, which are found in a wide range of natural and synthetic bioactive molecules.²⁵

There are numerous examples of the use of unsaturated aromatic- and aliphatic aldehydes with several 1,3-dicarbonyl compounds in intramolecular domino Knoevenagel-hetero-Diels-Alder reaction (DKHDA). However, the use of alkynes as dienophiles in DKHDA reactions is limited due to their low reactivity compared to alkenes.²⁶ In most of cases non-activated terminal alkynes have been used. Thus the pioneer works of Balalaie *et al* reported the use of CuI as an efficient Lewis acid for activation of various non-activated alkynes using different organic solvents,²⁷ inclusive trifluoroethanol.²⁸ In these cases the formation of an intermediate copper acetylide is postulated which is consistent with the observation that only terminal acetylenes participate in the reaction, and end-capped substrates do not undergo the cycloaddition reaction. Immobilized ZrO₂-nanopowder in the ionic liquid 1-butyl-3- methylimidazolium nitrate [bmim][NO₃] was used as a suitable Lewis-acid for DKHDA reactions with unactivated terminal alkynes.²⁹ Parmar *et al* reported a solvent-free tetrabutylammonium-hydrogensulfate catalysed DKHDA using 2- (alkynyloxy)acetophenones with pyrazolones.³⁰

Most of the examples of DKHDA with non-activated terminal alkynes use 1,3dicarbonyl compounds such as 1,3-indanedione,^{27a} Meldrum's acid and dimethyl

The Journal of Organic Chemistry

barbituric acid.³¹ Some active methylene compounds such as 4-hydroxy-coumarin,^{27c} benzoylacetonitrile,^{27b} 1-phenyl-3-methyl pyrazolone,^{30, 32} dihydroindole-2-thione, 4-hydroxydithiocoumarin³³ have been also used, but 2-hydroxy-1,4-benzoquinones have never been employed in this kind of transformation involving alkynes.

To the best of our knowledge, there are not any papers on intramolecular DKHDA reactions using non terminal alkynes type *O*-(arylpropynyloxy)-salicylaldehydes. Due to our interest in the preparation of bioactive embelin derivatives^{13a,13b, 25c} and, since this natural benzoquinone (1) contains a 2-hydroxy-1,4-quinonic moiety which is a synthetic equivalent to a 1,3-dicarbonyl compound, this molecule is an adequate substrate for DKHDA reactions using the mentioned non-terminal alkynes. Thus, a series of angular polycyclic embelin derivatives with two points of diversity could be obtained and some compounds result more selective and efficient than embelin (1) in biological bioassays.


Results and discussion

Compounds that contain an aldehyde functionality together with a suitably placed 3phenylprop-2-yn-1-oxy moiety are substrates which have never been studied before in the DKHDA protocol. These types of compounds were formed from the corresponding O-propargylated salicylaldehydes and aryl iodides *via* Sonogashira cross-coupling reactions. The starting O-propargylated salicylaldehydes (**4**) were obtained in excellent yields by reaction of salicylaldehyde derivatives and propargyl bromide using K₂CO₃ in dimethylformamide.³⁴

For the Sonogashira cross-coupling reactions, initially we selected the reaction conditions published by Kwong *et al* ³⁵ for the preparation of terminal-substituted alkynyl ethers. They used Pd(PPh₃)₂Cl₂ (3 mol%), Cu I (6 mol%), piperidine (2 equiv)

and dry toluene under nitrogen at 30°C. Using these conditions in the reaction of propargylated aldehyde **4a** and 1-iodo-4-methoxybenzene (**5a**), the resulting alkynyl ether (**6a**) was obtained in 56 % yield. In order to improve this yield we carried out the reaction using other aprotic and more polar solvents such as DMSO and DMF but we did not obtain a higher yield (43% DMSO, 58% DMF), only when THF was used a 86% yield was achieved. Table 1 summarizes the yields obtained in the preparation of a variety of aryl-substituted alkynyl ethers with two points of diversity.

Table 1. Preparation of aryl-substituted alkynyl ethers (6a-6ai)



Entry	R ₁	R ₂	product	yield (%) ^a
1	5-Cl	4-OCH ₃	6a	86
2	5-Cl	3-OCH ₃	6b	97
3	5-Cl	2-OCH ₃	6c	74
4	5-Cl	3-ОН	6d	69
5	5-C1	Н	6e	98
6	5-C1	3-NO ₂	6f	100
7	5-C1	3-CF ₃	6g	96
8	5-Br	4-OCH ₃	6h	85
9	5-Br	3-OCH ₃	6i	88
10	5-Br	2-OCH ₃	6j	57
11	5-Br	3-ОН	6k	38
12	5-Br	Н	61	94

Page 7 of 76

13	5-Br	3-NO ₂	6m	88	
14	5-Br	3-CF ₃	6n	82	
15	Н	4-OCH ₃	60	64	
16	Н	3-OCH ₃	6р	85	
17	Н	2-OCH ₃	6q	61	
18	Н	3-ОН	6r	83	
19	Н	Н	65	78	
20	Н	3-NO ₂	6t	84	
21	Н	3-CF ₃	6u	86	
22	4-OCH ₃	4-OCH ₃	6v	82	
23	4-OCH ₃	3-OCH ₃	6w	84	
24	4-OCH ₃	2-OCH ₃	6x	56	
25	4-OCH ₃	3-ОН	6 y	61	
26	4-OCH ₃	Н	6z	87	
27	4-OCH ₃	3-NO ₂	6aa	98	
28	4-OCH ₃	3-CF ₃	6ab	87	
29	$4-CO_2C_2H_5$	4-OCH ₃	6ac	85	
30	$4-CO_2C_2H_5$	3-OCH ₃	6ad	97	
31	$4-CO_2C_2H_5$	2-OCH ₃	6ae	59	
32	$4-CO_2C_2H_5$	3-ОН	6af	55	
33	$4-CO_2C_2H_5$	Н	6ag	98	
34	$4-CO_2C_2H_5$	3-NO ₂	6ah	90	
35	$4-CO_2C_2H_5$	3-CF ₃	6ai	100	
^a Isolated yield					

^aIsolated yield

The reaction appeared to be quite general with respect to a wide variety of functional groups such as -Cl, -Br, -OMe, and - $CO_2C_2H_5$ in salicylaldehyde. The best

yields were obtained with iodo-benzenes having electron-withdrawing substituents as 1iodo-3-nitrobenzene (entries 6, 13, 20, 27, 34) and 1-iodo-3-(trifluoromethyl)benzene (entries 7, 14, 21, 28, 35). However, the steric hindrance of the iodo-benzenes had significant effect on the reaction, and the yields were decreased for 1-iodo-2methoxybenzene (entries 3, 10, 17, 24, 31). Only in one case, with the bromosalicylaldehyde derivative (entry 10), together the formation of the corresponding arylsubstituted alkynyl ethers (**6j**, 57%), an alkyne dimer was also obtained in 26% yield.

To optimize the DKHDA reaction conditions, the reaction of compound **6a** and embelin (**1**) was chosen as a model reaction. We decided to carry out the reaction using ethylendiamine diacetate (EDDA, 10 mol %) as an effective organocatalyst for the initial Knoevenagel condensation. In the first attempt we investigated if in the absence of other additional catalyst, the DKHDA adduct could be formed. We were delighted to find that adduct **7a** was obtained in 23% in refluxing ethanol (Table 2, entry 1). A series of solvents (acetonitrile, toluene, dichloromethane, and dichloethane) were investigated (entries 2-5). Amongst the solvents tested, dichloroethane provided the best yield (entry 5). We also carried out the DKHDA reaction without EDDA (entry 6), and adduct **7a** was achieved in low yield (9%). When the reaction was performed at room temperature compound **7a** was obtained in 47% yield after 24 h (entry 7). In order to improve the yield, microwave irradiation was also used and, adduct **7a** was obtained in 93% yield in DCE at 120° C, for 10 min.




Table 2. Optimization of the DKHDA reaction between 1 and 6a

^aIsolated yield

With the optimized protocol in hand, the scope of this domino process was then assessed through the variation of aryl-substituted alkynyl ethers 6 (Table 3). Diversely substituted angular embelin adducts could be prepared in good yields (up to 100%), demonstrating the versatility of this domino process. As a general trend, the DKHDA reaction is tolerant to a large variety of aryl-substituted alkynyl ethers with electrondonating and electron-withdrawing groups. This substituent diversity results very attractive for the establishment of structure-activity relationships after biological evaluation.






Table 3. Synthesis of novel tetracyclic embelin adducts




The reaction can be rationalized *via* the formation of a Knoevenagel adduct intermediate, which undergoes an intramolecular hetero-Diels-Alder reaction to form **7** (Scheme 1). The process is regioselective since only the 1,4-benzoquinone adduct is obtained from the more electron-poor heterodiene. Two new fused rings next to the benzoquinone core and three σ bonds (two C-C σ bonds and one C-O σ bond) were formed in this domino reaction. The regiosubstitution of the corresponding adducts was confirmed by the two- and three-bond correlations detected in the HMBC spectrum and also by the ¹³C NMR chemical shifts of the quinone carbonyls.^{4f, 13b, 25} The introduction of a phenyl group in the alkyne favours the energy of HOMO of the dienophile and for this reason is not necessary an additional activation of the triple bond when aryl-end-capped alkynes are involved. In fact when the reaction of embelin was carried out with the terminal alkyne derivative **4a** (5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde) under the same reaction conditions (10 mol% EDDA, CH₂Cl₂, MW, 120 °C, 10 min) the formation of the corresponding adduct was not detected.



Scheme 1. Plausible formation of compounds 7

In order to see the scope of this protocol regarding the 1,3 dicarbonyl component, we carried out the DKHDA reaction with the following 1,3-dicarbonyl compounds: cyclohexanedione (8), dimedone (9) and barbituric acid (10). The active methylene compounds 4-hydroxy-6-methyl-2*H*-pyran-2-one (11), 4-hydroxycoumarin (12) and 2-hydroxy-1,4-naphthoquinone (13), which are of interest from a biological point of view, were also used. The results are summarized in Scheme 2. As we can see all enolizable symmetric cyclic 1,3-dicarbonyls annulated efficiently with 5-chloro-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6a) by this one-pot domino procedure. With respect to the compounds 11-13 two different products easy to separate by chromatography were obtained as a consequence of the cycloaddition reaction with the two heterodienes present in the corresponding Knoevenagel adduct intermediate. Thus from the reaction

with 4-hydroxy-6-methyl-2*H*-pyran-2-one (**11**), 4H-pyran-4-one (**17a**) and 2H-pyran-2one (**17b**) derivatives were formed in a 1:1 ratio. In a similar way the pyrano[2,3c]chromone (**18a**) and the pyrano[2,3-c]coumarin (**18b**) were obtained by using 4hydroxy-coumarin (**12**). In this case the compounds were obtained in a 1:1.5 ratio in favours of the coumarin derivative formed from the heterodiene intermediate involving the keto carbonyl group instead of the lactone carbonyl group. Finally when the DKHDA between **6a** and 2-hydroxynaphthoquinone (**13**) was carried out, the corresponding 1,4-naphthoquinone (**19a**) and 1,2-naphthoquinone (**19b**) were obtained in a 1.5:1 ratio in favours of the *p*-naphthoquinone formed from the more electron-poor heterodiene. The structures of the adducts (**14-19**) were unequivocally determined using 1D and 2D NMR spectroscopy.



Scheme 2. Scope of the reaction regarding 1,3-dicarbonyl compounds.

Conclusions

In conclusion, we have reported a microwave-assisted intramolecular approach for the synthesis of a set of new angular tetracyclic embelin derivatives. To the best of our knowledge, these are the first examples of intramolecular DKHDA reaction using *O*-(arylpropynyloxy)-salicylaldehydes. The presence of the phenyl group is essential to favours the intramolecular cycloaddition reaction. Diversely substituted embelin adducts could be prepared in good yields from a large variety of aryl-substituted alkynyl ethers with electron-donating and electron-withdrawing groups. This efficient organocatalyzed protocol was successfully applied to a variety of active methylene compounds. We expect that some of the synthesized compounds, with increased molecular complexity, result more active and selective than our starting compound, the natural benzoquinone embelin (1). The corresponding biological assays are in progress.

Experimental section

General Experimental Procedures. IR spectra were obtained using a Fourier Transform Infrared spectrometer. NMR spectra were recorded in CDCl₃ or DMSO at 500 or 600 MHz for ¹H NMR and 125 or 150 MHz for ¹³C NMR. Chemical shifts are given in (δ) parts per million and coupling constants (*J*) in hertz (Hz). ¹H and ¹³C spectra were referenced using the solvent signal as internal standard. Melting points were taken on a capillary melting point apparatus and are uncorrected. Microwave reactions were conducted in sealed glass vessels (capacity 5 mL) using a CEM Discover microwave reactor. HREIMS were recorded using a high-resolution magnetic trisector (EBE) mass analyzer. Analytical thin-layer chromatography plates used were Polygram-Sil G/UV254. Preparative thin-layer chromatography was carried out with Analtech silica gel GF plates (20 x 20 cm, 1000 Microns) using appropriate mixtures of ethyl acetate and hexanes. All solvents and reagents were purified by standard techniques

The Journal of Organic Chemistry

reported³⁶or used as supplied from commercial sources. All compounds were named using the ACD40 Name-Pro program, which is based on IUPAC rules. The embelin (1) used in the reactions was obtained from *Oxalis erythrorhiza Gillies ex Hook. & Arn.* following the procedure described in reference 5.

General Procedure for the Synthesis of *O*-propargylated salicylaldehydes (4a-4e). To a solution of the corresponding salicylaldehyde (1.0 mmol) in DMF (5 mL) was added anhydrous K_2CO_3 (152.7 mg, 1.1 mmol) followed by propargyl bromide (0.13 mL, 1.1 mmol). The reaction mixture was stirred at room temperature until disappearance of the starting salicylaldehyde. Ice water (100 mL) was then added and the product was quantitatively obtained by filtration.

5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde (4a). Following the general procedure, to a solution of 0.5 g (3.2 mmol) of 5-chlorosalicylaldehyde and 0.49 g (3.5 mmol) of K₂CO₃ in dry DMF (5 mL), 0.4 mL (3.5 mmol) of propargyl bromide was added to obtain the propargylated salicylaldehyde $4a^{34a}$ in a quantitative yield. ¹H-NMR (500 MHz, CDCl₃) δ 2.58 (1H, t, *J*=2.3 Hz), 4.83 (2H, d, *J* = 2.3 Hz), 7.09 (1H, d, *J* = 8.9 Hz), 7.51 (1H, dd, *J* = 2.7, 8.9 Hz), 7.81 (1H, d, *J*=2.7 Hz, 1H), 10.40 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 56.7 (CH₂), 76.9 (CH), 77.0 (C), 114.9 (CH), 126.4 (C), 127.5 (C), 128.2 (CH), 135.2 (CH), 158.1 (C), 188.2 (CH).

5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde (4b). Following the general procedure, to a solution of 0.5 g (2.5 mmol) of 5-bromosalicylaldehyde and 0.38 g (2.7 mmol) of K₂CO₃ in dry DMF (5 mL), 0.31 mL (2.7 mmol) of propargyl bromide was added to obtain the propargylated salicylaldehyde 4b^{34a} in a quantitative yield. ¹H-NMR (500 MHz, CDCl₃) δ 2.59 (1H, t, *J* = 2.4 Hz), 4.83 (2H, d, *J* = 2.4 Hz, 2H), 7.09 (d, *J* = 8.8 Hz, 1H), 7.51 (dd, *J* = 2.8, 8.9 Hz, 1H), 7.81 (d, *J* = 2.7 Hz, 1H), 10.41 (s, 1H); ¹³C-

NMR (125 MHz, CDCl₃) δ 55.8 (CH₂), 76.9 (CH), 77.2 (C), 115.0 (CH), 126.5 (C), 127.7 (C), 128.1 (CH), 135.2 (CH), 158.1 (C), 188.2 (CH).

2-(prop-2-yn-1-yloxy)benzaldehyde (4c). Following the general procedure, to a solution of 0.5 g (4.1 mmol) of salicylaldehyde and 0.62 g (4.5 mmol) of K₂CO₃ in dry DMF (5 mL), 0.5 mL (4.5 mmol) of propargyl bromide was added to obtain the propargylated salicylaldehyde $4c^{34a}$ in a quantitative yield.¹H-NMR (500 MHz, CDCl₃) δ 2.57 (1H, t, J = 2.2 Hz), 4.83 (2H, t, J = 2.4 Hz), 7.09 (1H, td, J = 2.9, 7.7 Hz), 7.12 (dd, J = 1.7, 8.4 Hz, 1H), 7.57 (m, 1H), 7.86 (ddd, J=1.7, 3.4, 7.6 Hz, 1H), 10.49 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 56.4 (CH₂), 76.5 (CH), 77.7 (C), 113.2 (CH), 121.7 (CH), 125.6 (C), 128.6 (CH), 135.7 (CH), 159.8 (C), 189.5 (CH).

4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde (*4d*). Following the general procedure, to a solution of 0.50 g (3.2 mmol) of 4-methoxysalicylaldehyde and 0.49 g (3.5 mmol) of K₂CO₃ in dry DMF (5 mL), 0.4 mL (3.5 mmol) of propargyl bromide was added to obtain the propargylated salicylaldehyde (*4d*)^{34b} in a quantitative yield. ¹H-NMR (500 MHz, CDCl₃) δ 2.58 (1H, t, *J*=2.4 Hz), 3.88 (3H, s), 4.80 (2H, d, *J*=2.4 Hz), 6.60 (m, 2H), 7.84 (1H, d, *J*=9.1 Hz, 1H), 10.30 (1H, s); ¹³C-NMR (125 MHz, CDCl₃) δ 55.7 (CH₃), 55.4 (CH₂), 76.6 (CH), 77.6 (C), 99.5 (CH), 106.8 (CH), 119.6 (C), 130.7 (CH), 161.5 (C), 165.9 (C), 188.1 (CH).

Ethyl-4-formyl-3-(prop-2-yn-1-yloxy)benzoate (**4e**). Following the general procedure, to a solution of 0.30 g (1.5 mmol) of 4-formyl-3-hydroxybenzoate and 0.24 g (1.7 mmol) of K₂CO₃ in dry DMF (5 mL), was added 0.15 mL (1.7 mmol) of propargyl bromide to obtain the propargylated salicylaldehyde **4e** in a quantitative yield.^{34b 1}H-NMR (500 MHz, CDCl₃) δ 1.39 (3H, t, *J*=7.3 Hz), 2.59 (1H, t, *J*=2.4 Hz), 4.37 (2H, q, *J*=7.2 Hz), 4.89 (1H, d, *J*=2.4 Hz), 7.17 (1H, d, *J*=8.7 Hz), 8.25 (2H, dd, *J*=2.3, 8.8 Hz, 2H), 8.51 (1H, d, *J*=2.3 Hz, 1H), 10.46 (s, 1H); ¹³C-NMR (125 MHz,

2	
3	
4	
5	
6	
7 8	
8	
9 10	
10	
11	
12	
13	
14	
14	
15	
16 17	
17	
18	
19	
20 21	
21	
21 22 23 24	
23	
21	
24	
25 26	
26	
27	
26 27 28	
29	
30	
31	
32	
32 33 34 35 36 37 38 39	
34	
35	
26	
30	
31	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40	
47 48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
50	
58 59	
59	
60	

CDCl₃) & 14.3 (CH₃), 56.7 (CH₂), 61.2 (CH₂), 76.9 (CH), 77.0 (C), 113.1 (CH), 124.5 (C), 125.3 (C), 130.6 (CH), 136.8 (CH), 162.6 (C), 165.4 (C), 188.5 (CH).

General Procedure for the Sonogashira Cross-Coupling of Aryl Iodides with Propargylated Salicylaldehydes

To a mixture of 50 mg of the propargylated salicylaldehyde, iodobenzene (1.1 equiv), and piperidine (2.0 equiv) in 1 mL of dry THF under an Ar atmosphere, Pd(PPh₃)₂Cl₂ (3 mol %) and CuI (6 mol %) were added successively. The reaction mixture was stirred at 30°C until complete consumption of starting salicylaldehyde. Then the solvent was removed under reduced pressure provided, and the residue was purified by column chromatography on silica gel (hexane/EtOAc) to afford the phenyl propargylated salicylaldehyde derivative.

5-*chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6a)*. Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde **4a** with 4-iodoanisole (67.2 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 2.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 66.9 mg (86%) of compound **6a** as a yellow oil. IR (neat) v_{max} 2256, 1696, 1632, 1523, 1474, 1432, 1325, 1225, 1202, 1187, 1154, 1122, 1032, 1010, 961, 897, 744, 705, 632 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.81 (s, 3H), 5.03 (s, 2H), 6.84 (d, *J* = 8.2 Hz, 2H), 7.18 (d, *J* = 8.6 Hz, 2H), 6.74 (s, 3H), 7.33 (d, *J* = 8.6 Hz, 2H), 7.52 (dd, *J* = 2.0, 8.6 Hz, 1H), 7.82 (d, *J* = 1.8 Hz, 1H), 10.45 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 57.8 (CH₂), 81.1 (C), 88.6 (C), 113.7 (C), 114.0 (CH x 2), 115.2 (CH x 2), 126.4 (C), 127.2 (C), 133.4 (CH x 2), 135.2 (CH), 158.5 (C), 160.2 (C), 188.5 (CH); EIMS *m/z* 300 (M⁺, 4), 286 (11), 277 (16), 262 (100), 183 (48), 155

(48); HREIMS 300.0565 (calcd for $C_{17}H_{13}O_3^{35}Cl (M^+)$ 300.0553), 287.0313 (calcd. for $C_{16}H_{10}O_3^{37}Cl (M^+-CH_3)$ 287.0289).

5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6b). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1yloxy)benzaldehyde with 3-iodoanisole (32.2 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol,) in dry THF (1 mL) under an Ar atmosphere at 30°C for 2.5h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 75.8 mg (97 %) of compound **6b** as a yellow oil. IR (neat) v_{max} 1670, 1589, 1473, 1400, 1288, 1258, 1223, 1180, 1126, 995, 957, 899, 810, 752, 687, 648 cm⁻ ¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.79 (s, 3H), 5.04 (s, 2H), 6.90 (ddd, J = 0.5, 2.5, 8.3Hz, 2H), 6.95 (dd, J= 1.3, 2.4 Hz, 1H), 7.01 (dt, J= 1.1, 7.6 Hz, 1H), 7.17 (d, J = 8.9 Hz, 1H), 7.22 (t, J= 8.1 Hz, 1H), 7.53 (dd, J = 2.7, 8.9 Hz, 1H), 7.82 (d, J= 2.7 Hz, 1H), 10.46 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 55.7 (CH₂), 57.3 (CH₃), 82.2 (C), 88.5 (C), 115.3 (CH), 115.6 (CH), 116.7 (CH), 122.6 (C), 124.3 (CH), 126.6 (C), 127.4 (C), 128.1 (CH), 129.5 (CH), 135.2 (CH), 158.4 (C), 159.4 (C), 188.3 (CH); EIMS m/z 300 ([M⁺], 10), 270 (1), 237 (1), 145 (100), 102 (13); HREIMS 302.0513 (calcd for $C_{17}H_{13}O_3^{37}Cl (M^+) 302.0524)$, 300.0540 (calcd. for $C_{17}H_{13}O_3^{35}Cl (M^+) 300.0553)$. 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6c). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-vn-1yloxy)benzaldehyde with 2-iodoanisole (35.1 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/ EtOAc,

 7:3) afforded 57.6 mg (74 %) of compound **6c**. IR (neat) v_{max} 2222, 1678, 1593, 1477, 1438, 1396, 1265, 1223, 1184, 1126, 1045, 1003, 960, 895, 810, 744, 706, 644 cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 3.85 (s, 3H), 5.09 (s, 2H), 6.87 (d, *J* = 8.5 Hz, 1H), 6.90 (td, *J* = 0.9, 7.5 Hz, 1H), 7.24 (d, *J*= 8.9 Hz, 1H), 7.32 (m, 1H), 7.36 (dd, *J*= 1.6, 7.5 Hz, 1H), 7.52 (dd, *J* = 2.9, 8.9 Hz, 1H), 7.82 (d, *J* = 2.7 Hz, 1H), 10.46 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.8 (CH₂), 58.1 (CH₂), 85.1 (C), 86.4 (C), 110.7 (CH), 110.8 (C), 115.6 (CH), 120.5 (CH), 126.6 (C), 127.2 (C), 127.9 (CH), 130.6 (CH), 133.7 (CH), 135.1 (CH), 158.6 (C), 160.3 (C), 188.5 (CH); EIMS *m/z* 300 (M⁺, 4), 281 (4), 262 (3), 182 (2), 145 (100), 115 (39); HREIMS 302.0540 (calcd for C₁₇H₁₃O₃³⁷Cl (M⁺) 302.0524), 300.0537 (calcd. for C₁₇H₁₃O₃³⁵Cl (M⁺) 300.0553).

5-*chloro-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6d)*. Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-hydroxyphenol (59.4 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 2.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 51.4 mg (69 %) of compound **6d**. IR (neat) ν_{max} 1674, 1577, 1439, 1412, 1373, 1292, 1269, 1199, 1126, 1022, 987, 894, 814, 783, 744, 687 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.02 (s, 2H), 6.85 (dd, *J* = 2.0, 8.1 Hz, 1H), 6.90 (dd, *J* = 1.4, 2.3 Hz, 1H), 7.08 (dt, *J* = 1.3, 7.7 Hz, 1H), 7.16 (m, 2H), 7.52 (dd, *J* = 2.7, 8.8 Hz, 1H), 7.81 (d, *J* = 2.6 Hz, 1H), 10.43 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.8 (CH₂), 82.3 (C), 88.3 (C), 115.4 (CH), 116.7 (CH), 118.5 (CH), 122.7 (C), 124.2 (CH), 126.4 (C), 127.4 (C), 128.1 (CH), 129.7 (CH), 135.4 (CH), 155.5 (C), 158.5 (C), 188.9 (CH); EIMS *m/z* 286 (M⁺, 13), 262 (11), 219 (60), 183 (10), 131 (100); HREIMS 288.0356

(calcd. for $C_{16}H_{11}O_3^{37}Cl (M^+) 288.0367$), 286.0387 (calcd. for $C_{16}H_{11}O_3^{35}Cl (M^+)$ 286.0397).

5-chloro-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6e). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde with iodobenzene (35.5 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 69.0 mg (98 %) of compound **6e**³⁷ as a yellow oil. IR (neat) v_{max} 1678, 1597, 1574, 1477, 1415, 1377, 1272, 1238, 1207, 1173, 1123, 1049, 995, 895, 810, 779, 709, 687, 667 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.04 (s, 2H), 7.17 (d, *J* = 8.8 Hz, 1H), 7.32 (m, 3H), 7.41 (m, 2H), 7.52 (dd, *J* = 2,8, 8.8 Hz, 1H), 7.82 (d, *J* = 2.7 Hz, 1H), 10.45 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.3 (CH₂), 82.4 (C), 88.6 (C), 115.3 (CH), 121.7 (C), 126.6 (C), 127.4 (C), 128.1 (CH), 128.4 (CH x 2), 131.8 (CH x 2), 135.2 (CH), 158.5 (C), 188.3 (CH); EIMS *m*/*z* 270 (M⁺, 16), 240 (2), 207 (2), 154 (3), 115 (100); HREIMS 272.0425 (calcd for C₁₆H₁₁O₂³⁷Cl (M⁺) 272.0418), 270.0455 (calcd, for C₁₆H₁₁O₂³⁵Cl (M⁺) 270.0448).

5-chloro-2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6f).

Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-nitro-iodobenzene (67.2 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 82.8 mg (100 %) of compound **6f**. IR (neat) v_{max} 3522, 3398, 3086, 1674, 1589, 1524, 1477, 1350, 1227, 1169, 1061, 976, 902, 814, 737, 671 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.07 (s, 2H), 7.14 (d, *J* = 8.9 Hz, 1H), 7.52 (t, *J*=8.0 Hz, 1H), 7.55 (dd, *J*= 2.7, 8.7 Hz, 1H), 7.72 (dt, *J*= 1.2, 7.7 Hz, 1H), 7.84 (d, *J*= 2.7 Hz, 1H), 8.21 (ddd, *J*= 1.1, 2.3, 8.3 Hz, 1H), 8.28 (t, *J*= 1.8 Hz, 1H), 10.46 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.3 (CH₂), 85.1 (C), 85.9 (C), 115.0 (CH), 123.5 (C), 123.8 (CH), 126.5 (C), 126.6 (CH), 127.6 (C), 128.3 (C), 129.6 (C), 135.3 (CH), 137.5 (CH), 148.1 (C), 158.2 (C), 188.1 (CH); EIMS *m*/*z* 300 (M⁺, 10), 270 (1), 237 (1), 145 (100), 102 (13); HREIMS 302.0513 (calcd for C₁₇H₁₃O₃³⁷Cl (M⁺) 302.0524), 300.0540 (calcd. for C₁₇H₁₃O₃³⁵Cl (M⁺) 300.0553).

5-chloro-2-((3-(4-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6g).

Following the general procedure, the treatment of 50 mg (0.26 mmol) of 5-chloro-2-

(prop-2-yn-1-yloxy)benzaldehyde with 4-trifluoromethyl-1-iododbenzene (38.9 µL,

0.27 mmol), Pd(PPh₃)₂Cl₂ (5.4 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 84.9 mg (96 %) of compound **6g** as a oil yellow. IR (neat) ν_{max} 3522, 3398, 3074, 2874, 1682, 1593, 1744, 1331, 1258, 1215, 1161, 1084, 976, 899, 802, 683 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.06 (s, 2H), 7.15 (d, *J* = 8.9 Hz, 1H), 7.46 (t, *J* = 7.7 Hz, 1H), 7.54 (dd, *J* = 2,7, 8.7 Hz, 1H), 7.60 (t, *J* = 7.3 Hz, 2H), 7.68 (s, 1H), 7.83 (d, *J* = 2.8 Hz, 1H), 10.45 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.4 (CH₂), 84.0 (C), 86.9 (C), 115.0 (CH), 122.6 (C), 125.6 (CH, *J*_{C-F}= 2.7 Hz), 126.5 (C), 127.5 (C), 128.2 (CH x 2), 128.6 (C, *J*_{C-F}= 3.7 Hz), 129.0 (CH), 131.1 (C, *J*_{C-F}= 34.1 Hz), 134.9 (CH), 135.2 (CH), 158.2 (C), 188.1 (CH); EIMS *m/z* 338 (M⁺, 16), 308 (3), 272 (5), 182 (100); HREIMS 302.0513 (calcd for C₁₇H₁₃O₃³⁷Cl 302.0524), 300.0540 (calcd. for C₁₇H₁₃O₃³⁵Cl 300.0553).

5-bromo-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6h). Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-vn-1yloxy)benzaldehyde with 4-iodoanisole (51.6 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 4:1) afforded 58.4 mg (85 %) of compound **6h** as a yellow oil. IR (neat) v_{max} 2218, 2203, 1678, 1597, 1508, 1474, 1400, 1292, 1254, 1238, 1192, 1254, 1238, 1192, 1123, 1029, 1018, 999, 972, 922, 879, 791, 640, 621 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.80 (s, 3H), 5.03 (s, 2H), 6.83 (d, J = 7.8 Hz, 2H), 7.12 (d, J = 9.1 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.65 (dd, J = 2.5, 8.8 Hz, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.52 (dd, J = 2.0, 8.6 Hz, 1H), 7.82 (d, J = 1.8 Hz, 1H), 10.45 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 57.7 (CH₂), 81.1 (C), 88.6 (C), 113.7 (C), 114.0 (CH x 2), 114.4 (C), 115.6 (CH), 126.9 (C), 131.1 (CH), 133.4 (CH x 2), 138.1 (CH), 159.0 (C), 160.2 (C), 188.3 (CH); EIMS *m*/*z* 344 (M⁺, 29), 314 (6), 262 (4), 145 (100), 102 (70); HREIMS 346.0019 (calcd for $C_{17}H_{13}O_3^{81}Br$ 346.0028), 344.0067 (calcd. for $C_{17}H_{13}O_3^{79}Br$ 344.0048).

5-bromo-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (**6i**). Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodoanisole (26.3 μ L, 0.27 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 4:1) afforded 63.7 mg (88 %) of compound **6i**³⁸ as a yellow oil. IR (neat) ν_{max} 1674, 1589, 1477, 1377, 1323, 1269, 1230, 1207, 1180, 1122, 1084, 1041, 1022, 1003, 987,

883, 837, 783, 702, 682, 652 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.78 (s, 3H), 5.03 (s, 2H), 6.90 (ddd, J = 0.8, 2.6, 8.2 Hz, 1H), 6.93 (dd, J = 1.6, 2.5 Hz, 1H), 7.01 (dt, J = 1.2, 7.7 Hz, 1H), 7.11 (d, J = 8.9 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.65 (dd, J = 2.6, 8.8 Hz, 1H), 7.96 (d, J = 2.6 Hz, 1H), 10.43 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 57.6 (CH₂), 82.1 (C), 88.5 (C), 114.4 (C), 115.5 (CH), 115.6 (CH), 116.7 (CH), 122.6 (C), 124.3 (CH), 126.8 (C), 129.5 (CH), 131.1 (CH), 138.1 (CH), 158.9 (C), 159.3 (C), 188.2 (CH); EIMS *m/z* 344 (M⁺, 14), 314 (2), 262 (2), 145 (100), 102 (30); HREIMS 346.0036 (calcd for C₁₇H₁₃O₃⁸¹Br 346.0028), 344.0050 (calcd. for C₁₇H₁₃O₃⁷⁹Br 344.0048).

5-bromo-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6j). Following the general procedure, treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 2-methoxy-1-iodobenzene (28.7 μ L, 0.22 mmol), Pd(PPh₃)₂Cl₂ (3% mol, 4.4 mg), CuI (6% mol, 2.5 mg) and piperidine (2 eq. 0.5 mmol, 42 μ L) in dry THF (1 ml) under an Ar atmosphere at 30°C for 2.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/AcOEt, 7:3), afforded the corresponding product 6j (50.7 mg, 70%) together the alkyne dimer 6j' (13.3 mg, 25%).

6j: IR (neat) v_{max} 3526, 3402, 2874, 2223, 1686, 1589, 1477, 1385, 1265, 1223, 1061, 1007, 957, 891, 810, 744, 648, 633 cm⁻¹;¹H-NMR (500 MHz, CDCl₃) δ 3.86 (s, 3H), 5.09 (s, 2H), 6.87 (d, J = 8.3 Hz, 1H), 6.90 (td, J = 1.2, 7.8 Hz, 1H), 7.19 (d, J = 8.8 Hz, 1H), 7.32 (ddd, J = 1.7, 7.9, 8.3 Hz), 7.36 (dd, J = 1.7, 7.6 Hz, 1H), 7.66 (dd, J = 2.6, 8.9 Hz, 1H), 7.96 (d, J = 2.7 Hz, 1H), 10.44 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.8 (CH₃), 58.0 (CH₂), 85.1 (C), 86.4 (C), 110.7 (CH), 110.8 (C), 114.4 (C), 116.0 (CH), 120.5 (CH), 126.9 (C), 130.6 (CH), 131.0 (CH), 133.7 (CH), 138.0 (CH), 159.0 (C), 160.3 (C), 188.4 (CH); EIMS m/z 345 ((M+1)⁺, 3), 328 (2), 262 (30), 183 (14), 145

(100); HREIMS 346.0041 (calcd for $C_{17}H_{13}O_3^{81}Br$ 346.0028), 344.0052 (calcd. for $C_{17}H_{13}O_3^{79}Br$ 344.0048).

6j': IR (neat) v_{max} 3522, 3398, 1620, 1473, 1396, 1061, 972, 852, 806, 667 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 4.90 (s, 2H), 6.97 (d, J = 8.7 Hz, 1H), 7.66 (dd, J = 2.6, 8.8Hz, 1H), 7.96 (d, J = 2.6 Hz, 1H), 10.37 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.0 (CH₂), 71.9 (C), 73.8 (C), 115.0 (C), 115.1 (CH), 126.8 (C), 131.4 (CH), 138.2 (CH), 158.3 (C), 187.8 (CH); ESI(+)-MS *m/z* 498 ((M+Na)⁺, 100), 449 (52); HR-ESIMS 496.9000 (calcd. for C₂₀H₁₂O₄⁷⁹Br₂Na 496.8994), 498.8980 (calcd. for $C_{20}H_{12}O_4^{79}Br^{81}BrNa$ 496.8994), 500.8959 (calcd. for $C_{20}H_{12}O_4^{81}Br_2Na$ 500.8969). 5-bromo-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6k). Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1yloxy)benzaldehyde with 3-iodophenol (48.5 mg, 0.22 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 3:7), afforded 26.7 mg (38%) of compound **6k** as a yellow oil. IR (neat) v_{max} 1678, 1589, 1469, 1439, 1392, 1269, 1269, 1207, 1180, 1123, 1011, 991, 879, 852, 810, 771, 682, 651 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.03 (s, 2H), 6.84 (dd, J = 2.4, 8.1 Hz, 1H), 6.89 (dd, J = 1.2, 2.5 Hz, 1H), 6.98 (dt, J = 1.2, 7.6 Hz, 2H), 7.11 (d, J = 8.9 Hz), 7.18 (t, J = 7.8 Hz, 1H), 7.67 (dd, J = 2.6, 8.9 Hz, 1H), 7.96 (d, J = 2.7 Hz, 1H), 10.42 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 57.6 (CH₂), 82.3 (C), 88.2 (C), 114.5 (C), 114.9 (C), 115.7 (CH), 116.6 (CH), 118.4 (CH), 122.7 (C), 124.3 (CH), 129.7 (CH), 131.2 (CH), 138.2 (CH), 155.5 (C), 158.9 (C), 188.6 (CH); EIMS *m/z* 329 (M⁺, 5), 277 (15), 219 (68), 199 (100), 130 (49); HREIMS 331.9885 (calcd for C₁₆H₁₁O₃⁸¹Br 331.9871), 329.9887 (calcd. for $C_{16}H_{11}O_3^{79}Br$ 329.9892).

5-bromo-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6l). Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodobenzene (29.0 μL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 μL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 4:1) afforded 62.1 mg (94 %) of compound $6l^{38}$ as a yellow oil. IR (neat) ν_{max} 2987, 2886, 2233, 1647, 1585, 1474, 1458, 1400, 1276, 1223, 1122, 1180, 1157, 1142, 1069, 995, 957, 887, 806, 752, 686, 652 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.04 (s, 2H), 7.13 (d, *J* = 8.9 Hz, 1H), 7.33 (m, 3H), 7.42 (m, 2H), 7.66 (dd, *J* = 2.6, 8.8 Hz, 1H), 7.97 (d, *J* = 2.6 Hz, 1H), 10.44 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.6 (CH₂), 82.3 (C), 88.6 (C), 114.5 (C), 115.6 (CH), 121.7 (C), 126.9 (C), 128.4 (CH x 2), 129.1 (CH), 131.2 (CH), 131.8 (CH x 2), 138.1 (CH), 158.9 (C), 188.2 (CH); EIMS *m/z* 316 (M⁺, 55), 287 (8), 235 (7), 207 (9), 115 (100); HREIMS 315.9923 (calcd for C₁₆H₁₁O₂⁸¹Br 315.9922), 313.9933 (calcd. for C₁₆H₁₁O₂⁷⁹Br 313.9942).

5-bromo-2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6m). Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-nitro-1-iodobenzene (54.9 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 66.9 mg (88 %) of compound 6m as a yellow oil. IR (neat) v_{max} 1682, 1589, 1524, 1466, 1393, 1342, 1273, 1219, 1177, 1119, 1018, 979, 879, 814, 733, 671, 652 cm⁻¹; ¹H-NMR (500 MHz,CDCl₃) δ 5.07 (s, 2H), 7.09 (d, *J* = 8.9 Hz, 1H), 7.52 (t, *J* = 8.0 Hz, 1H), 7.66 (dd, *J* = 2.6, 8.9 Hz, 1H), 7.72 (dt, *J* = 1.3, 7.7 Hz, 1H),

ACS Paragon Plus Environment

7.89 (d, J = 2.6 Hz, 1H), 8.21 (ddd, J = 1.0, 2.3, 8.3 Hz, 1H), 8.28 (t, J = 1.8 Hz, 1H), 10.44 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.3 (CH₂), 85.0 (C), 86.0 (C), 114.8 (C), 115.3 (CH), 123.4 (C), 123.8 (CH), 124.9 (C), 126.7 (CH), 126.9 (C), 129.6 (CH), 131.4 (CH), 137.5 (CH), 138.2 (CH), 158.6 (C), 188.0 (CH); EIMS *m/z* 360 (M⁺, 9), 330 (3), 252 (5), 160 (100), 114 (56); HREIMS 360.9779 (calcd for C₁₆H₁₀NO₄⁸¹Br 360.9773), 358.9785 (calcd. for C₁₆H₁₀NO₄⁷⁹Br 358.9793).

5-bromo-2-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6n).

Following the general procedure, the treatment of 50 mg (0.21 mmol) of 5-bromo-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-trifluoromethyl-1-iodobenzene 3-nitro-1iodobenzene (31.8 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (4.4 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (42 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 66.4 mg (82 %) of compound **6n** as a yellow oil. IR (neat) v_{max} 1682, 1589, 1470, 1435, 1393, 1331, 1273, 1219, 1177, 1157, 1115, 1099, 1076, 1007, 972, 883, 806, 690, 660 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.05 (s, 2H), 7.09 (d, J = 8.9 Hz, 1H), 7.46 (t, J = 7.8Hz, 1H), 7.59 (dd, J = 1.8, 7.7 Hz, 2H), 7.67 (m, 2H), 7.96 (d, J = 2.6 Hz, 1H), 10.43 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.4 (CH₂), 84.0 (C), 86.9 (C), 114.6 (C), 115.3 (CH), 122.6 (C), 125.7 (CH, J_{C-F}= 3.7 Hz), 127.9 (C, J_{C-F}= 268.7 Hz), 128.6 (CH, J_{C-F}= 3.9 Hz), 129.0 (CH), 131.1 (C, J_{C-F}= 33.6 Hz), 130.4 (C), 131.3 (CH), 134.9 (CH), 138.1 (CH), 158.7 (C), 188.1 (CH); EIMS *m/z* 381 (M⁺, 25), 352 (8), 275 (11), 182 (100); HREIMS 383.9793 (calcd for $C_{17}H_{10}F_3O_2^{81}Br$ 383.9796), 381.9824 (calcd. for C₁₇H₁₀F₃O₂⁷⁹Br 381.9816).

2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (60). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde

with 4-iodoanisole (76.7 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 53.0 mg (64 %) of compound **60**³⁷ as a yellow oil. IR (neat) ν_{max} 3521, 3398, 2237, 1682, 1597, 1508, 1458, 1223, 1099, 1030, 957, 825, 752, 640 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.80 (s, 3H), 5.04 (s, 2H), 6.83 (d, *J* = 8.7 Hz, 2H), 7.08 (t, *J* = 7.5 Hz, 1H), 7.21 (d, *J* = 8.4 Hz, 1H), 7.37 (d, *J* = 8.7 Hz, 2H), 7.57 (m, 1H), 7.87 (dd, *J* = 1.5, 7.7 Hz, 1H), 10.53 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 57.5 (CH₂), 81.6 (C), 88.1 (C), 113.5 (CH), 113.9 (C), 114.0 (CH x 2), 121.5 (CH), 125.6 (C), 128.5 (CH), 133.4 (CH x 2), 135.7 (CH₂), 160.1 (C), 160.2 (C), 189.8 (CH); EIMS *m/z* 266 (M⁺, 20), 237 (7), 145 (100), 102 (10); HREIMS 266.0945 (calcd for C₁₇H₁₄O₃ (M⁺) 266.0943).

2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6p). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodoanisole (39 µL, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 70.4 mg (85 %) of compound **6p** as a yellow oil. IR (neat) v_{max} 1682, 1593, 1458, 1369, 1285, 1261, 1211, 1157, 1103, 1042, 1022, 987, 864, 833, 791, 764, 687, 648 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.78 (s, 3H), 5.04 (s, 2H), 6.89 (ddd, *J* = 0.9, 2.6, 8.3 Hz, 1H), 6.95 (dd, *J* = 1.4, 2.5 Hz, 1H), 7.02 (dt, *J* = 1.2, 7.7 Hz, 1H), 7.08 (m, 1H), 7.21 (m, 2H), 7.57 (ddd, *J* = 1.8, 7.3, 9.0 Hz, 1H), 7.87 (dd, *J* = 1.8, 7.7 Hz, 1H), 10.53 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.2 (CH₃), 57.3 (CH₂), 82.7 (C), 88.0 (C), 113.4 (CH),

115.4 (CH), 116.7 (CH), 121.5 (CH), 122.8 (C), 124.2 (CH), 125.5 (C), 128.5 (CH), 129.4 (CH), 135.7 (CH), 159.3 (C), 160.0 (C), 189.6 (CH); EIMS m/z 266 (M⁺, 44), 237 (10), 145 (100), 102 (17); HREIMS 266.0958 (calcd for $C_{17}H_{14}O_3$ (M⁺) 266.0943). 2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6q). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 2-iodoanisole (42.6 µL, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 50.0 mg (61 %) of compound **6q** as a yellow oil. IR (neat) v_{max} 2233, 1686, 1597, 1481, 1458, 1369, 1265, 1250, 1215, 1161, 1099, 1018, 960, 833, 752, 694, 648 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.85 (s, 3H), 5.09 (s, 2H), 6.86 (d, J = 8.4 Hz, 1H), 6.89 (td, J = 1.0, 7.5Hz, 1H), 7.07 (m, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.30 (ddd, J = 1.8, 7.5, 9.2 Hz, 1H), 7.37 (dd, J = 1.7, 7.6 Hz, 1H), 7.57 (ddd, J = 1.9, 7.3, 9.1 Hz, 1H), 7.87 (dd, J = 1.8, 7.7Hz, 1H), 10.54 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 55.7 (CH₃), 57.6 (CH₂), 84.6 (C), 86.9 (C), 110.6 (CH), 111.0 (C), 113.7 (CH), 120.4 (CH), 121.4 (CH), 125.5 (C), 128.3 (CH), 129.5 (C), 130.4 (CH), 133.7 (CH), 135.6 (CH), 160.2 (C), 189.8 (CH); EIMS *m*/*z* 266 (M⁺, 10), 249 (14), 235 (10), 145 (100), 115 (50); HREIMS 266.0935 (calcd for $C_{17}H_{14}O_3$ (M⁺) 266.0943).

2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (**6***r*). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodophenol (72.1 mg, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 64.8 mg

(78 %) of compound **6r**. IR (neat) v_{max} 3398, 2924, 1682, 1597, 1470, 1288, 1211, 1053, 787, 756, 687, 652 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.87 (s, 1H), 4.99 (s, 2H), 6.59 (ddd, J = 0.6, 2.1, 8.5 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 1.8, 8.1 Hz, 1H), 6.93 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 10.30 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.4 (CH₂), 82.9 (C), 87.7 (C), 113.6 (CH), 116.4 (CH), 118.4 (CH), 121.6 (CH), 123.0 (C), 124.4 (CH), 125.6 (C), 128.6 (CH), 129.7 (CH), 135.8 (CH), 155.4 (C), 160.1 (C), 189.9 (CH); HRESIMS 275.0688 (calcd. for C₁₆H₁₂O₃Na 275.0684).

2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6s). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde (0.31 mmol) with iodobenzene (43.1 µL, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 56.8 mg (78 %) of compound **6s**.³⁹ IR (neat) v_{max} 1678, 1659, 1593, 1481, 1458, 1400, 1373, 1285, 1261, 1218, 1192, 1165, 1107, 1042, 995, 957, 914, 829, 756, 725, 687, 652, 609 cm⁻¹. ¹H-RMN (500 MHz, CDCl₃) δ 5.05 (s, 2H), 7.09 (t, *J* = 7.0 Hz, 1H), 7.21 (d, *J* = 8.7 Hz, 1H), 7.32 (m, 3H), 7.43 (m, 2H), 7.58 (ddd, *J* = 1.8, 7.5, 9.0 Hz, 1H), 7.88 (dd, *J* = 1.7, 7.7 Hz, 1H), 10.54 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.3 (CH₂), 82.9 (C), 88.1 (C), 113.4 (CH), 121.5 (CH), 121.9 (C), 125.6 (C), 128.3 (CH x 2), 128.5 (CH), 128.9 (CH), 131.8 (CH x 2), 135.7 (CH), 160.1 (C), 189.7 (CH); EIMS *m/z* 236 (M⁺, 77), 206 (50), 120 (45), 114 (100); HREIMS 236.0836 (calcd for C₁₆H₁₂O₂ (M⁺) 236.0837).

2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6t). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde

(0.31 mmol) with 3-nitro-1-iodobenzene (81.6 mg, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 73.2 mg (84 %) of compound **6t**. IR (neat) v_{max} 1678, 1593, 1535, 1481, 1458, 1369, 1346, 1285, 1234, 1161, 1103, 1022, 999, 879, 844, 810, 764, 733, 667 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.07 (s, 2H), 7.11 (m, 1H), 7.17 (d, *J* = 8.4 Hz, 1H), 7.50 (t, *J* = 8.0 Hz, 1H), 7.60 (ddd, *J* = 1.9, 7.3, 9.1 Hz, 1H), 7.72 (td, *J* = 1.3, 7.8 Hz, 1H), 7.88 (dd, *J* = 1.8, 7.7 Hz, 1H), 8.18 (ddd, *J* = 1.1, 2.3, 8.4 Hz, 1H), 8.26 (t, *J* = 1.8 Hz, 1H), 10.52 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 56.9 (CH₂), 85.5 (C), 85.6 (C), 113.2 (CH), 121.8 (CH), 123.6 (CH), 125.6 (C), 126.6 (CH), 128.7 (CH), 129.5 (CH), 130.2 (C), 135.8 (CH), 137.4 (CH), 148.1 (C), 159.8 (C), 189.4 (CH); EIMS *m/z* 281 (M⁺, 45), 252 (14), 234 (8), 159 (100), 114 (81); HREIMS 281.0700 (calcd for C₁₆H₁₁O₄N (M⁺) 281.0688).

2-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (**6***u*). Following the general procedure, the treatment of 50 mg (0.31 mmol) of 2-(prop-2-yn-1-yloxy)benzaldehyde (0.31 mmol) with 3-trifluoromethyl-1-iodobenzene (42.3 µL, 0.32 mmol), Pd(PPh₃)₂Cl₂ (6.6 mg, 3 mol %), CuI (3.6 mg, 6 mol %) and piperidine (60 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (hex/EtOAc, 7:3) afforded 81.1 mg (86 %) of compound **6u** as a yellow oil. IR (neat) v_{max} 1678, 1597, 1481, 1458, 1396, 1331, 1288, 1219, 1157, 1119, 1072, 1011, 976, 903, 833, 798, 760, 690, 660 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 5.06 (s, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 7.44 (t, *J* = 7.8 Hz, 2H), 7.59 (m, 3H), 7.68 (s, 1H), 7.88 (dd, *J* = 1.4, 7.7 Hz, 1H), 10.53 (s, 1H); ¹³C-NMR (125 MHz,

ACS Paragon Plus Environment

CDCl₃) δ 57.1 (CH₂), 84.6 (C), 86.4 (C), 113.3 (CH), 121.7 (CH), 122.8 (C), 123.5 (C, J_{C-F} = 274.6 Hz), 125.5 (CH, J_{C-F} = 3.5 Hz), 125.6 (C), 128.6 (CH, J_{C-F} = 3.8 Hz), 128.7 (CH), 128.9 (CH), 131.0 (C, J_{C-F} = 30.6 Hz), 134.9 (CH), 135.8 (CH), 159.9 (C), 189.5 (CH); EIMS *m*/*z* 304 (M⁺, 27), 276 (7), 183 (100), 133 (3); HREIMS 304.0718 (calcd for C₁₇H₁₁O₂F₃ (M⁺) 304.0711).

4-methoxy-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6v). Following the general procedure, the treatment of 50 mg (0.26 mmol) of of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde with 4-iodoanisole (64.6 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 4.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex: EtOAc, 7:3) afforded 63.5 mg (82 %) of compound **6v** as a yellow oil. IR (neat) v_{max} 1666, 1601, 1504, 1454, 1439, 1381, 1315, 1288, 1265, 1207, 1169, 1111, 1057, 1011, 953, 868, 825, 794, 675 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.80 (s, 3H), 3.88 (s, 3H), 5.01 (s, 2H), 6.60 (dd, *J* = 2.2, 8.7 Hz, 1H), 6.69 (d, *J* = 2.2 Hz, 2H), 6.84 (d, *J* = 8.7, 2H), 7.37 (d, *J* = 8.7 Hz, 2H), 7.84 (d, *J* = 8.7 Hz, 1H), 10.34 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 55.7 (CH₃), 57.5 (CH₂), 81.5 (C), 88.3 (C), 99.6 (CH), 106.8 (CH), 113.9 (C), 114.0 (CH x 2), 119.6 (C), 130.5 (CH), 133.4 (CH x 2), 160.1 (C), 161.9 (C), 165.9 (C), 188.3 (CH); EIMS *m/z* 296 (M⁺, 11), 267 (7), 237 (1), 144 (100), 102 (11); HREIMS 296.1041 (calcd for C₁₈H₁₆O₄ (M⁺) 296.1049).

4-methoxy-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (**6**w). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde with 4-iodoanisole (32.8 μ L, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under

reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 65 mg (84 %) of compound **6w** of yellow oil. IR (neat) v_{max} 1674, 1601, 1577, 1485, 1439, 1373, 1315, 1261, 1204, 1168, 1107, 1034, 991, 933, 860, 825, 771, 744. 683 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) & 3.79 (s, 3H), 3.88 (s, 3H), 5.02 (s, 2H), 6.60 (ddd, J = 0.5, 2.2, 8.9 Hz, 1H), 6.68 (d, J = 2.5 Hz, 1H), 6.90 (ddd, J = 0.9, 2.7, 8.3Hz, 1H), 6.96 (dd, J = 1.5, 2.6 Hz, 1H), 7.03 (dt, J = 1.1, 7.5 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 10.35 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.3 (CH₃), 55.7 (CH₃), 57.3 (CH₂), 82.6 (C), 88.1 (C), 99.6 (CH), 106.8 (CH), 115.5 (CH), 119.7 (CH), 119.6 (C), 122.9 (C), 124.3 (CH), 129.5 (CH), 130.6 (CH), 159.3 (C), 161.8 (C), 165.9 (C), 188.3 (CH); EIMS *m/z* 296 (M⁺, 64), 268 (67), 237 (10), 145 (100), 102 (66); HREIMS 296.1044 (calcd for $C_{18}H_{16}O_4$ (M⁺) 296.1049). 4-methoxy-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6x). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde with 2-iodoanisole (35.9 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 43.3 mg (56 %) of compound **6x**. IR (neat) v_{max} 2839, 2233, 1674, 1597, 1493, 1435, 1258, 1161, 1107, 1014, 825, 752, 683, 644 cm⁻¹: ¹H-NMR (500 MHz, CDCl₃) & 3.85 (s, 3H), 3.89 (s, 3H), 5.07 (s, 2H), 6.60 (dd, J= 1.6, 8.6 Hz, 1H), 6.77 (d, J= 2.0 Hz, 1H), 6.87 (d, J= 8.6 Hz, 1H), 6.89 (t, J= 7.8 Hz, 1H), 7.3 (td, J= 1.3, 7.9 Hz, 1H), 7.40 (dd, J= 1.4, 7.6 Hz, 1H), 7.83 (d, J= 8.7 Hz, 1H), 10.35 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 55.6 (CH₃), 55.7 (CH₃), 57.6 (CH₂), 84.8 (C), 86.8 (C), 99.7 (CH), 107.0 (CH), 110.7 (CH), 120.4 (CH), 127.6 (C), 130.4 (CH), 130.5 (CH), 133.8 (CH), 135.2 (C), 160.4 (C), 162.0 (C), 165.9 (C), 188.4 (CH); EIMS

m/z 296 (M⁺, 21), 268 (34), 262 (27), 145 (100), 115 (64); HREIMS 296.1042 (calcd for C₁₈H₁₆O₄ (M⁺) 296.1049).

4-methoxy-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6y). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde with 3-iodoanisole (60.7 mg, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 44.7 mg (61 %) of compound **6y** as a yellow oil. IR (neat) v_{max} 3205, 2939, 2847, 2230, 1666, 1601, 1574, 1497, 1393, 1292, 1261, 1173, 1134, 1119, 1022, 991, 864, 837, 683 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.87 (s, 1H), 4.99 (s, 2H), 6.59 (ddd, J = 0.6, 2.1, 8.5 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 1.8, 8.1 Hz, 1H),6.93 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 10.30 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 55.7 (CH₃), 57.4 (CH₂), 82.5 (C), 88.1 (C), 99.6 (CH), 107.1 (CH), 116.6 (CH), 118.5 (CH), 119.4 (C), 122.8 (C), 124.0 (CH), 129.6 (CH), 130.8 (CH), 155.9 (C), 162.0 (C), 166.2 (C), 188.9 (CH); EIMS m/z 282 (M⁺, 15), 254 (24), 223 (4), 151 (33), 131 (100); HREIMS 282.0880 (calcd for $C_{17}H_{14}O_4 (M^+) 282.0892).$

4-methoxy-2-((3-phenylprop-2-yn-1-yl)oxy)benzaldehyde (6z). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1-yloxy)benzaldehyde (0.26 mmol) with 3-iodobenzene (36.3 μ L, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 μ L, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 60.5 mg (87 %) of compound **6z** as a

yellow oil. IR (neat) v_{max} 1674, 1597, 1492, 1443, 1373, 1258, 1191, 1157, 1092, 1157, 1092, 1030, 964, 822, 756, 690 cm⁻¹;¹H-NMR (500 MHz, CDCl₃) δ 3.88 (s, 3H), 5.02 (s, 2H), 6.60 (ddd, J = 0.4, 2.1, 6.5 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 7.33 (m, 3H), 7.43 (m, 2H), 7.85 (d, J = 8.7 Hz, 1H), 10.35 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.7 (CH₃), 57.3 (CH₂), 82.8 (C), 88.2 (C), 99.5 (CH), 106.8 (CH), 119.6 (C), 121.9 (C), 128.4 (CH x 2), 128.9 (CH), 130.6 (CH), 131.8 (CH x 2), 161.8 (C), 165.9 (C), 188.2 (CH); EIMS *m*/*z* 266 (M⁺, 11), 238 (20), 207 (3), 151 (7), 115 (100); HREIMS 266.0934 (calcd for C₁₇H₁₄O₃ (M⁺) 266.0943).

4-methoxy-2-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6aa). Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-(prop-2-yn-1yloxy)benzaldehyde with 3-iodobenzene (36.3 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (hex/EtOAc, 7:3) afforded 79.1 mg (98 %) of compound **6aa** as a yellow oil. IR (neat) v_{max} 1678, 1605, 1527, 1501, 1462, 1439, 1373, 1353, 1261, 1196, 1165, 1111, 1026, 945, 906, 829, 806, 737, 671 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.89 (s, 3H), 5.04 (s, 2H), 6.63 (m, 2H), 7.51 (t, J= 7.9 Hz, 1H), 7.74 (dt, J= 1.3, 7.8 Hz, 1H), 7.86 (d, J= 8.4 Hz, 1H), 8.20 (ddd, J= 1.0, 2.3, 8.3 Hz, 1H), 8.28 (t, J= 1.8 Hz, 1H), 10.34 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) & 55.2 (CH₃), 56.9 (CH₂), 85.5 (C), 85.5 (C), 99.6 (CH), 106.7 (CH), 119.5 (C), 123.6 (CH), 126.6 (CH), 129.5 (CH), 130.8 (CH), 137.4 (CH), 148.0 (C), 161.4 (C), 165.9 (C), 188.0 (CH); EIMS *m*/*z* 311 (M⁺, 9), 283 (84), 236 (9), 160 (100), 133 (30), 114 (75); HREIMS 311.0791 (calcd for $C_{17}H_{13}O_5N (M^+) 311.0794$). 4-methoxy-2-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde (6ab).

Following the general procedure, the treatment of 50 mg (0.26 mmol) of 4-methoxy-2-

(prop-2-yn-1-yloxy)benzaldehyde (0.26 mmol) with 3-trifluoromethyl-1-iodobenzene (39.8 µL, 0.27 mmol), Pd(PPh₃)₂Cl₂ (5.5 mg, 3 mol %), CuI (2.9 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 75.5 mg (87 %) of compound **6ab** as a yellow oil. IR (neat) v_{max} 1663, 1597, 1504, 1462, 1435, 1389, 1327, 1258, 1204, 1153, 1119, 1096, 1069, 1026, 999, 906, 833, 798, 740, 698, 663 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.89 (s, 1H), 5.03 (s, 2H), 6.62 (dd, *J* = 2.1, 8.7 Hz, 1H), 6.66 (d, *J* = 2.6 Hz, 1H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.59 (t, *J* = 6.3 Hz, 2H), 7.70 (s, 1H), 7.86 (d, *J* = 8.8 Hz, 1H), 10.35 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 57.1 (CH₂), 84.6 (C), 86.44 (C), 113.3 (CH), 121.7 (CH), 122.8 (C), 123.5 (C, *J*_{C-F}= 274.6 Hz), 125.5 (CH, *J*_{C-F}= 3.5 Hz), 125.6 (C), 128.6 (CH, *J*_{C-F}= 3.8 Hz), 128.7 (CH), 128.9 (CH), 131.0 (C, *J*_{C-F}= 30.6 Hz), 134.9 (CH), 135.8 (CH), 159.9 (C), 189.5 (CH); EIMS *m/z* 334 (M⁺, 21), 305 (78), 275 (8), 182 (100), 133 (9); HREIMS 334.0823 (calcd for C₁₈H₁₃O₃F₃ (M⁺) 334.0817).

Ethyl 4-formyl-3-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate (6ac). Following the general procedure, the treatment of 50 mg (0.23 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with 4-iodoanisole (52.9 mg, 0.32 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (51 µL, 0.5 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 3 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 61.6 mg (83 %) of compound 6ac as a yellow oil. IR (neat) v_{max} 3522, 3398, 2893, 2225, 1701, 1605, 1500, 1366, 1246, 1177, 1142, 1126, 1045, 1026, 829, 764, 690 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.38 (t, *J* = 7.1 Hz, 3H), 3.79 (s, 3H), 4.37 (g, *J* = 7.1 Hz, 2H), 5.09 (s, 2H), 6.82 (d, *J* = 8.8 Hz, 2H), 7.26 (d, *J* = 8.8 Hz, 1H),

7.35 (d, J = 8.8, 2H), 8.26 (dd, J = 2.4, 8.8 Hz, 1H), 8.52 (d, J = 2.3 Hz, 1H), 10.50 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.3 (CH₃), 55.3 (CH₃), 57.8 (CH₂), 61.1 (CH₂), 80.9 (C), 88.9 (C), 113.3 (CH), 113.8 (C), 114.2 (CH x 2), 124.2 (C), 125.3 (C), 130.5 (CH), 133.4 (CH x 2), 136.7 (CH), 160.4 (C), 163.0 (C), 165.5 (C), 188.7 (CH); EIMS m/z 338 (M⁺, 61), 309 (21), 262 (22), 145 (100), 102 (39), HREIMS 338.1171 (calcd for C₂₀H₁₈O₅ (M⁺) 338.1154).

Ethyl 4-formyl-3-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate (6ad). Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2yn-1-yloxy)benzoate with 3-iodoanisole (26.9 µL, 0.23 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 µL, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 71.9 mg (97 %) of compound **6ad** as a yellow oil. IR (neat) v_{max} 2885, 2858, 2237, 1701, 1605, 1492, 1377, 1292, 1238, 1188, 1142, 1018, 984, 849, 768, 687, 659. 629 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.38 (t, J = 7.2 Hz, 3H), 3.77 (s, 3H), 4.37 (g, J = 7.2 Hz, 2H), 5.10 (s, 2H), 6.89 (ddd, J = 0.8, 2.6, 8.3 Hz, 1H), 6.94 (dd, J =1.2, 2.6 Hz, 1H), 7.00 (dt, J = 0.8, 7.5 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 8.8Hz, 1H), 8.26 (dd, J = 2.3, 8.8 Hz, 1H), 8.50 (d, J = 2.3 Hz, 1H), 10.50 (s, 1H);¹³C-NMR (125 MHz, CDCl₃) & 14.3 (CH₃), 55.3 (CH₃), 57.6 (CH₂), 61.1 (CH₂), 82.0 (C), 88.7 (C), 113.2 (CH), 115.7 (CH), 116.9 (CH), 122.7 (C), 124.3 (C), 124.4 (CH), 125.3 (C), 129.5 (CH), 130.6 (CH), 136.7 (CH), 159.5 (C), 162.9 (C), 165.4 (C), 188.6 (CH); EIMS *m*/*z* 338 (M⁺, 65), 309 (11), 293 (11), 145 (100), 115 (24), 102 (46); HREIMS 338.1168 (calcd for $C_{20}H_{18}O_5$ (M⁺) 338.1154).

Ethyl 4-formyl-3-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate (6ae). Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-

yn-1-yloxy)benzoate with 2-iodoanisole (26.4 μL, 0.23 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 μL, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 44.2 mg (59 %) of compound **6ae** as a yellow oil. IR (neat) ν_{max} 3533, 2977, 2233, 1708, 1686, 1605, 1493, 1369, 1304, 1242, 1169, 1103, 1022, 995, 941, 829, 760, 748, 694 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.39 (t, *J* = 7.2 Hz, 3H), 3.84 (s, 3H), 4.38 (q, *J* = 7.2 Hz, 2H), 5.15 (s, 2H), 6.86 (d, *J* = 8.1 Hz, 1H), 6.89 (dd, *J* = 0.9, 7.6 Hz, 1H), 7.30 (ddd, *J* = 1.7, 7.7, 9.2 Hz, 1H), 7.33 (d, *J* = 8.8 Hz, 1H), 7.36 (dd, *J* = 1.7, 7.5 Hz, 1H), 8.26 (dd, *J* = 2.2, 8.7 Hz, 1H), 8.53 (d, *J* = 2.2 Hz, 1H), 10.51 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.3 (CH₃), 55.8 (CH₃), 58.0 (CH₂), 61.1 (CH₂), 85.5 (C), 86.2 (C), 111.0 (CH), 111.1 (C), 113.7 (CH), 120.5 (CH), 124.2 (C), 125.4 (C), 130.4 (CH), 130.6 (CH), 133.8 (CH), 136.7 (CH), 160.6 (C), 163.1 (C), 165.5 (C), 188.8 (CH); EIMS *m*/z 338 (M⁺, 17), 320 (22), 262 (31), 183 (19), 145 (100), 115 (79); HREIMS 338.1168 (calcd for C₂₀H₁₈O₅ (M⁺) 338.1154).

Ethyl 4-formyl-3-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzoate (6af). Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with 3-iodophenol (49.7 mg, 0.23 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 μ L, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 39.5 mg (55 %) of compound **6af** as a yellow oil. IR (neat) ν_{max} 3391, 3028, 1686, 1601, 1489, 1443, 1296, 1261, 1180, 1103, 1018, 984, 957, 868, 768, 687, 656 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.38 (t, *J* = 7.3 Hz, 3H), 4.37 (q, *J* = 7.1 Hz, 2H), 4.95 (s, 1H), 5.09 (s, 1H), 6.83 (ddd, *J* = 1.1, 2.9, 8.3 Hz, 1H), 6.89 (dd, *J* = 1.1, 1.1, 2.9, 8.3 Hz, 1H), 6.89 (dd, J = 1.1, 1.1)

2.4 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.24 (s, 1H), 8.26 (dd, J = 2.2, 8.7 Hz, 1H), 8.52 (d, J = 2.2 Hz, 1H), 10.49 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.3 (CH₃), 57.5 (CH₃), 61.3 (CH₂), 82.0 (C), 88.5 (C), 113.2 (CH), 115.0 (C), 116.7 (CH), 118.5 (CH), 122.7 (C), 124.3 (CH), 124.9 (C), 129.7 (CH), 130.7 (CH), 137.0 (CH), 155.6 (C), 162.9 (C), 165.7 (C), 189.1 (C); EIMS *m/z* 324 (M⁺, 22), 262 (41), 182 (24), 131 (100); HREIMS 324.1024 (calcd. for C₁₉H₁₆O₅ (M⁺) 324.0998).

Ethyl 4-formyl-3-((3-phenylprop-2-yn-1-yl)oxy)benzoate (**6ag**). Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with iodophenol (29.7 µL, 0.23 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 µL, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 66.2 mg (98 %) of compound **6ag** as a yellow oil. IR (neat) v_{max} 2989, 2858, 1705, 1605, 1493, 1443, 1366, 1254, 1188, 1149, 1014, 995, 848, 756, 687, 663, 648 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.39 (t, *J* = 7.1 Hz, 3H), 4.36 (q, *J* = 7.1 Hz, 2H), 5.11 (s, 2H), 7.29 (m, 4H), 7.41 (m, 2H), 7.26 (dd, *J* = 2.2, 8.8 Hz, 1H), 8.53 (d, *J* = 2.3 Hz, 1H), 10.51 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.3 (CH₃), 57.7 (CH₂), 61.1 (CH₂), 82.3 (C), 88.8 (C), 113.3 (CH), 121.8 (C), 123.3 (C), 125.4 (C), 128.4 (CH x 2), 129.1 (CH), 130.6 (CH), 131.8 (CH x 2), 136.7 (CH), 162.9 (C), 165.4 (C), 188.6 (CH); EIMS *m/z* 308 (M⁺, 100), 263 (27), 193 (16), 165 (10), 115 (99); HREIMS 308.1050 (calcd. for C₁₉H₁₆O₄ (M⁺) 308.1049).

Ethyl 4-formyl-3-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzoate (6ah). Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with iodophenol (56.3 mg, 0.23 mmol), $Pd(PPh_3)_2Cl_2$ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 µL, 0.43 mmol) in dry THF (1 mL) under

ACS Paragon Plus Environment

an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (hex/EtOAc, 7:3) afforded 69.6 mg (90 %) of compound **6ah** as a yellow oil. IR (neat) v_{max} 3521, 3398, 1686, 1609, 1531, 1366, 1057, 987, 848, 725, 667 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.37 (t, J = 7.2 Hz, 3H), 4.36 (q, J = 7.2 Hz, 2H), 5.14 (s, 2H), 7.23 (d, J = 8.8 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.70 (dt, J = 1.2, 7.7 Hz, 1H), 8.17 (ddd, J = 1.0, 2.3, 8.4 Hz, 1H), 8.24 (t, J = 1.8 Hz, 1H), 8.26 (dd, J = 2.3, 8.8 Hz, 1H), 8.51 (d, J = 2.2 Hz, 1H), 10.49 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.3 (CH₃), 57.2 (CH₂), 61.1 (CH₂), 84.9 (C), 86.1 (C), 114.0 (CH), 123.5 (C), 123.8 (CH), 124.5 (C), 125.3 (C), 126.6 (CH), 129.5 (CH), 130.7 (CH), 136.8 (CH), 137.4 (CH), 148.2 (C), 162.6 (C), 165.3 (C), 188.4 (CH); EIMS *m*/z 353 (M⁺, 20), 308 (11), 279 (4), 206 (7), 160 (100), 114 (36); HREIMS 353.0915 (calcd. for C₁₉H₁₅O₆N (M⁺) 353.0899). *Ethyl 4-formyl-3-((3-(trifluoromethylphenyl)prop-2-yn-1-yl)oxylbenzoate* (**6ai**).

Following the general procedure, the treatment of 50 mg (0.22 mmol) of ethyl 4-formyl-3-(prop-2-yn-1-yloxy)benzoate with 3-trifluoromethyl-1-iodobenzene (56.3 mg, 0.23 mmol), Pd(PPh₃)₂Cl₂ (4.8 mg, 3 mol %), CuI (2.5 mg, 6 mol %) and piperidine (43 µL, 0.43 mmol) in dry THF (1 mL) under an Ar atmosphere at 30°C for 1.5 h, followed by evaporation of the solvent under reduced pressure and purification on silica gel column chromatography (Hex/EtOAc, 7:3) afforded 83.7 mg (100 %) of compound **6ai** as a yellow oil. IR (neat) v_{max} 3514, 3402, 1712, 1689, 1612, 1434, 1385, 1319, 1061, 968, 825, 687, 667, 629 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 1.38 (t, *J* = 7.4 Hz, 3H), 4.37 (q, *J* = 7.1 Hz, 2H), 5.12 (s, 2H), 7.23 (d, *J* = 8.9 Hz, 1H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.57 (s, 1H), 7.59 (s, 1H), 7.67 (s, 1H), 8.23 (dd, *J* = 2.2, 8.7 Hz, 1H), 8.53 (d, *J* = 2.2 Hz, 1H), 10.50 (s, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 55.7 (CH₃), 57.1 (CH₂), 84.4 (C), 86.6 (C), 99.6 (CH), 106.7 (CH), 119.6 (C), 122.8 (C), 123.5 (C, *J*_{CF}= 275.5 Hz), 125.5 (CH, J_{C-F} = 3.6 Hz), 128.6 (CH, J_{C-F} = 3.0 Hz), 129.0 (CH), 130.8 (CH), 131.0 (C, J_{C-F} = 33.4 Hz), 134.9 (CH), 160.6 (C), 165.9 (C), 188.1 (CH); EIMS *m/z* 376 (M⁺, 21), 347 (8), 330 (5), 275 (4), 182 (100); HREIMS 376.0911 (calcd. for C₂₀H₁₅O₄F₃ (M⁺) 376.0922).

General Procedures for the preparation of pyran embelin derivatives via DKHDA

A solution of embelin (30.0 mg, 0.10 mmol) in dichloroethane (5 mL), 0.15 mmol of the corresponding alkyne and 10 mol % of EDDA was placed in a microwave-special closed vial and the solution was irradiated for 10 min in a single-mode microwave oven (120 °C). The reaction mixture was then cooled to room temperature. After removal of the solvent under reduced pressure, the product was purified by preparative-TLC using Hex/EtOAc to yield the corresponding pyran derivatives.

11-chloro-2-hydroxy-6-(4-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-

1,4(7H, 12bH)-dione (7a). Following the general procedure described above, 26.1 mg (0.09 mmol) of embelin, 40 mg (0.1 mmol) of 5-chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.02 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 47.8 mg (93%) of 7a as a brown solid. Mp: 148.8-149.4 °C; IR (neat) ν_{max} 3348, 2923, 2853, 1687, 1651, 1619, 1608, 1513, 1479, 1400, 1345, 1323, 1305, 1248, 1220, 1172, 1116, 1085, 1023, 983, 870, 842, 814 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=6.9 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.50 (t, *J*=7.7 Hz, 2H), 3.83 (s, 3H), 4.82 (s, 1H), 4.86 (d, *J*=12.6 Hz, 1H), 4.89 (d, *J*=12.9 Hz, 1H), 6.65 (d, *J*=1.4 Hz, 1H), 6.76 (d, *J*=8.8 Hz, 1H), 6.93 (d, *J*=8.8 Hz, 2H), 7.09 (dd, *J*=1.9, 8.8 Hz, 1H), 7.33 (d, J=8.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.7 (CH₂ x 2), 30.9 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.8

(CH₂), 106.8 (C), 110.5 (C), 113.9 (CH x 2), 118.9 (CH), 119.6 (C), 123.4 (C), 123.6 (C), 125.3 (CH), 125.9 (C), 128.2 (CH), 129.0 (C), 129.9 (CH x 2), 145.2 (C), 152.2 (C), 152.6 (C), 160.8 (C), 180.0 (C), 183.3 (C); EIMS *m/z* 576 (M⁺, 100), 548 (22), 436 (20), 407 (39), 283 (51), 135 (87); HREIMS 578.2284 (calcd for $C_{34}H_{37}O_6^{37}Cl$ 578.2249), 576.2286 (calcd for $C_{34}H_{37}O_6^{35}Cl$ 576.2279).

11-chloro-2-hydroxy-6-(3-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-

1,4(7H,12bH)-dione (7b). Following the general procedure described above, 45.6 mg (0.16 mmol) of embelin, 70 mg (0.23 mmol) of 5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.8 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 90.4 mg (98%) of 7b as a brown solid. Mp: 81.8-82.9 °C; IR (neat) v_{max} 3315, 2924, 2853, 1640, 1625, 1598, 1480, 1431, 1345, 1261, 1177, 1119, 1092, 1043, 1024, 990, 887, 819 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.2 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J=7.7 Hz, 2H), 3.82 (s, 3H), 4.83 (s, 1H), 4.88 (s, 2H), 6.66 (d, J=1.5 Hz, 1H), 6.76 (d, J = 8.6 Hz, 1H), 6.94 (m, 3H), 7.10 (dd, J = 2.2, 8.7 Hz, 1H), 7.32 (t, J = 7.8 Hz. 1H): ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (2xCH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (2xCH₂), 29.7 (2xCH₂), 30.9 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.7 (CH₂), 108.1 (C), 110.5 (C), 113.9 (CH), 115.8 (CH), 116.8 (C), 118.9 (CH), 119.7 (C), 120.9 (CH), 125.3 (CH), 126.0 (C), 128.3 (CH), 129.0 (C), 129.6 (CH), 132.4 (C), 145.1 (C), 152.1 (C), 152.6 (C), 159.6 (C), 179.9 (C), 183.4 (C); EIMS *m/z* 578 (M⁺, 16), 558 (10), 481 (34), 338 (12), 135 (100); HREIMS 576.2268 (calcd for $C_{34}H_{37}O_6^{35}Cl 576.2279$), 578.2264 (calcd for $C_{34}H_{37}O_6^{35}Cl 578.2249$). 11-chloro-2-hydroxy-6-(2-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7c). Following the general procedure described above, 32.6 mg

(0.11 mmol) of embelin, 50 mg (0.17 mmol) of 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.8 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 41.5 mg (65%) of 7c as a brown solid. Mp: 121.5-122.8 °C; IR (neat) v_{max} 3363, 2924, 2853, 2360, 2338, 1697, 1652, 1620, 1600, 1479, 1348, 1254, 1229, 1178, 1118, 1089, 1049, 1019, 989, 820 cm⁻ ¹;¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.1 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.48 (t, J=7.4 Hz, 2H), 3.79 (s, 3H), 4.47 (d, J=12.5 Hz, 1H), 4.74 (d, J=13.0 Hz, 1H), 4.83 (s, 1H), 6.67 (s, 1H), 6.73 (d, J = 8.6 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 6.99 (t, J=7.3 Hz, 1H), 7.08 (d, J =7.8 Hz, 1H), 7.30 (dd, J =1.0, 7.5 Hz, 1H), 7.39 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) & 14.1 (CH₃), 22.7 (CH₂ x 2), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (2xCH₂), 29.7 (CH₂ x 2), 30.8 (CH), 31.9 (CH₂), 55.7 (CH₃), 68.1 (CH₂), 109.3 (C), 110.5 (C), 111.4 (CH), 115.7 (C), 118.7 (CH), 119.5 (C), 120.7 (CH), 125.3 (CH), 125.5 (C), 128.1 (CH), 128.7 (C), 130.9 (CH), 131.6 (CH), 133.7 (C), 135.1 (C), 141.7 (C), 152.9 (C), 157.2 (C), 180.0 (C), 183.7 (C); EIMS *m/z* 576 (M⁺, 35), 527 (53), 437 (26), 386 (33), 282 (37); HREIMS 576.2268 (calcd for C₃₄H₃₇O₆³⁵Cl 576.2279). 11-chloro-2-hydroxy-6-(3-hydroxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7d). Following the general procedure described above, 27.3 mg of embelin (0.09 mmol), 40 mg (0.14 mmol) of 5-chloro-2-((3-(3-hydroxyphenyl)prop-2yn-1-yl)oxy)benzaldehyde) and 1.7 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 41.6 mg (82%) of 7d as a brown solid. Mp: 145.6-146.1 °C; IR (neat) v_{max} 3335, 2921, 2852, 1645, 1613, 1584, 1480, 1400, 1346, 1328, 1273, 1250, 1220, 1194, 1168, 1117, 1089, 1029, 979, 934, 878, 912 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.0 Hz, 3H), 1.26 (sa, 16H),

1.52 (m, 2H), 2.50 (t, *J*=7.7 Hz, 2H), 4.83 (s, 1H), 4.87 (s, 2H), 5.45 (bs, 1H), 6.66 (s, 1H), 6.77 (d, *J* = 8.6 Hz, 1H), 6.88 (m, 3H), 7.00 (dd, *J* =1.5, 8.4 Hz, 1H), 7.25 (m, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (2xCH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (CH₂ x 2), 30.9 (CH), 31.9 (CH₂), 67.7 (CH₂), 108.2 (C), 110.5 (C), 115.3 (CH), 117.2 (CH), 119.0 (CH), 119.7 (C), 120.9 (CH), 125.3 (CH), 126.0 (C), 128.3 (CH), 128.9 (C), 129.8 (CH), 132.5 (C), 144.9 (C), 151.2 (C), 152.1 (C), 152.6 (C), 155.8 (C), 180.1 (C), 183.3 (C); EIMS *m*/*z* 562 (M⁺, 79), 548 (40), 421 (40), 268 (87), 135 (93); HREIMS 564.2114 (calcd. for C₃₃H₃₅O₆³⁷Cl 564.2093), 562.2137 (calcd. for C₃₃H₃₅O₆³⁵Cl 562.2122). 11-chloro-2-hydroxy-6-phenyl-3-undecylchromeno[3,4-c]chromene-1,4(7H, 12bH)-dione

(**7e**). Following the general procedure described above, 25.3 mg (0.09 mmol) of embelin, 35 mg (0.13 mmol) of 5-chloro-2-((3-(3-phenyl)prop-2-yn-1-

yl)oxy)benzaldehyde and 1.6 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 34.6 mg (74%) of **7e** as a brown solid. Mp: 146.2-146.7 °C; IR (neat) v_{max} 3338, 2921, 2851, 1653, 1481, 1401, 1347, 1325, 1249, 1218, 1170, 1116, 1091, 1069, 1020, 1009, 984, 921, 870, 814 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.0 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, *J*=7.5 Hz, 2H), 4.84 (s, 1H), 4.86 (d, *J*=12.9 Hz, 1H), 4.90 (d, *J*=12.9 Hz, 1H), 6.66 (d, *J*=1.0 Hz, 1H), 6.76 (d, *J*=8.6 Hz, 1H), 7.09 (dd, *J*=1.1, 8.9 Hz, 1H), 7.42 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (2xCH₂), 28.1 (CH₂), 29.4 (2 x CH₂), 29.6 (2 x CH₂), 29.7 (2 x CH₂), 30.9 (CH), 31.9 (CH₂), 67.7 (CH₂), 107.9 (C), 110.5 (C), 118.9 (CH), 119.7 (C), 125.3 (CH), 126.0 (C), 128.3 (CH), 128.5 (2 x CH), 128.6 (2 x CH), 128.9 (C), 130.0 (CH), 131.2 (C), 145.3 (C), 151.2 (C), 152.2 (C), 152.6 (C), 179.9 (C), 183.5 (C); EIMS *m/z* 546 (M⁺, 91), 518 (35), 405 (43), 294 (37), 252 (100);

HREIMS 546.2156 (calcd for $C_{33}H_{35}O_5^{35}Cl$ 546.2173), 548.2122 (calcd for $C_{33}H_{35}O_5^{37}Cl$ 548.2144).

11-chloro-2-hydroxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7f). Following the general procedure described above, 24.8 mg (0.08 mmol) of embelin, 40 mg of 5-chloro-2-((3-(3-nitrophenyl)prop-2-yn-1yl)oxy)benzaldehyde (0.13 mmol) and 1.5 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 50.8 mg (100%) of 7f as a brown solid. Mp: 154.1-156.0 °C; IR (neat) v_{max} 3523, 3397, 2924, 2853, 1652, 1622, 1532, 1479, 1346, 1256, 1223, 1170, 1113, 1098, 1032, 987, 951, 906, 860, 813 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.0 Hz, 3H), 1.24 (bs, 16H), 1.50 (m, 2H), 2.50 (t, J=8.9 Hz, 2H), 4.77 (d, J=12.9 Hz, 1H), 4.85 (s, 1H), 4.96 (d, J=13.3 Hz, 1H), 6.67 (s, 1H), 6.78 (d, J = 8.4 Hz, 1H), 7.10 (d, J=7.7 Hz, 1H), 7.63 (t, J=7.6 Hz, 1H), 7.76 (d, J=7.2 Hz, 1H), 8.23 (s, 1H), 8.28 (d, J=8.1 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) § 14.0 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.2 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (2xCH₂), 29.7 (2xCH₂), 30.9 (CH), 31.9 (CH₂), 67.2 (CH₂), 110.4 (C), 110.6 (C), 119.1 (CH), 119.9 (C), 120.0 (C), 123.4 (CH), 124.7 (CH), 125.3 (CH), 126.3 (C), 128.5 (CH), 128.6 (C), 129.8 (CH), 132.9 (C), 134.2 (CH), 142.9 (C), 148.2 (C), 151.8 (C), 152.4 (C), 179.5 (C), 182.5 (C); EIMS *m/z* 591 (M⁺, 100), 573 (70), 450 (50), 421 (43), 297 (59); HREIMS 593.1968 (calcd. for C₃₃H₃₄NO₇³⁷Cl, 593.1994), 591.2000 (calcd. for $C_{33}H_{34}NO_7^{35}Cl, 591.2024).$

11-chloro-2-hydroxy-6-(3-(trifluoromethyl)phenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7g). Following the general procedure described above, 23.2 mg of embelin (0.08 mmol), 40 mg of 5-chloro-2-((3-(3-trifluoromethylphenyl)prop-2-yn-1yl)oxy)benzaldehyde (0.12 mmol) and 1.5 mg of EDDA (10 mol %) were suspended in

2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 41.4 mg (86%) of **7g** as an amorphous brown solid. Mp: 184.3-186.0 °C; IR (neat) v_{max} 3774, 3534, 3357, 2925, 2854, 1707, 1650, 1619, 1481, 1395, 1336, 1216, 1166, 1066, 810 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.1 Hz, 3H), 1.26 (bs, 16H), 1.52 (m, 2H), 2.51 (t, *J* = 7.7 Hz, 2H), 4.79 (d, *J* = 12.8 Hz, 1H), 4.87 (s, 1H), 4.93 (d, *J* = 12.8 Hz, 1H), 6.67 (dd, *J* = 1.0, 2.5 Hz, 1H), 6.79 (d, *J* = 8.6 Hz, 1H), 7.12 (dd, *J* = 2.4, 8.7, 1H), 7.59 (m, 2H), 7.65 (s, 1H), 7.70 (dt, *J* = 2.5, 7.9 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (2xCH₂), 29.7 (CH₂), 29.8 (CH₂), 30.9 (CH), 31.9 (CH₂), 67.4 (CH₂), 110.5 (C), 110.6 (C), 119.1 (CH), 119.9 (C), 125.2 (CH), 125.3 (CH), 126.3 (C), 126.8 (CH, *J* _{C-F} = 3.7 Hz), 128.5 (CH), 128.7 (C), 129.3 (CH), 131.4 (C), 131.8 (CH), 132.1 (C), 143.9 (C), 151.1 (C), 151.8 (C), 152.4 (C), 179.7 (C), 183.3 (C); EIMS *m*/*z* 614 (M⁺, 86), 596 (76), 444 (38), 320 (67), 173 (87); HREIMS 614.2047 (calcd for C₃₄H₃₄O₅³⁵ClF₃ 614.2047), 616.1998 (calcd for C₃₄H₃₄O₅³⁵ClF₃ 616.2017).

11-bromo-2-hydroxy-6-(4-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7h). Following the general procedure described above, 23.8 mg (0.09 mmol) of embelin, 40 mg (0.12 mmol) of 5-chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 36.7 mg (73%) of 7h as an amorphous brown solid; Mp: 140.4-142.0 °C; IR (neat) v_{max} 3349, 2922, 2852, 1651, 1619, 1608, 1513, 1476, 1344, 1249, 1219, 1176, 1117, 1088, 1022, 1004, 983, 918, 841, 812 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.0 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, *J*=7.6 Hz, 2H), 3.83 (s, 3H), 4.82 (s, 1H), 4.86 (d, *J*=12.9 Hz, 1H), 4.89 (d, *J*=12.9 Hz, 1H), 6.71 (d, *J*=8.8 Hz, 1H), 6.78 (d, *J*=1.2 Hz, 1H), 6.93 (d, *J*=8.8 Hz, 2H), 7.23 (dd, *J*=2.1, 8.6 Hz, 1H), 7.33 (d, *J*=8.8 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (3x CH₂), 29.7 (CH₂), 30.8 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.8 (CH₂), 106.7 (C), 110.4 (C), 113.2 (C), 113.9 (2 x CH), 119.4 (CH), 119.6 (C), 123.6 (C), 128.1 (CH), 129.5 (C), 129.9 (2 x CH), 131.2 (CH), 145.2 (C), 151.1 (C), 152.2 (C), 153.1 (C), 160.8 (C), 180.0 (C), 183.4 (C); EIMS *m*/*z* 622 (M⁺, 100), 620 (84), 452 (21), 328 (29), 262 (53); HREIMS 622.1757 (calcd for C₃₄H₃₇O₆⁸¹Br 622.1753), 620.1788 (calcd for C₃₄H₃₇O₆⁷⁹Br 620.1774).

11-bromo-2-hydroxy-6-(3-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7i). Following the general procedure described above, 34.2 mg of embelin (0.12 mmol), 60 mg de 5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1yl)oxy)benzaldehyde (0.17 mmol) and 2.1 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 58.3 mg (81%) of 7i as a yellow oil; IR (neat) v_{max} 3374, 3055, 2926, 2854, 2361, 2339, 1694, 1646, 1624, 1598, 1477, 1431, 1347, 1263, 1174, 1120, 1082, 1025, 988, 892, 864, 819 cm⁻¹; ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta 0.87 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.25 \text{ (bs, 16H)}, 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 2.50 \text{ (t, } J = 7.1 \text{ Hz}, 3\text{H}), 1.50 \text{ (m, 2H)}, 1.5$ 7.4 Hz, 2H), 3.82 (s, 3H), 4.82 (s, 1H), 4.88 (s, 2H), 6.70 (d, J = 8.5 Hz, 1H), 6.79 (s, 1H), 6.95 (m, 3H), 7.22 (d, J = 7.8 Hz, 1H), 7.32 (t, J = 7.8 Hz, 1H); ¹³C NMR (125) MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.2 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.7 (CH₂), 29.7 (CH₂), 30.8 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.7 (CH₂), 108.0 (C), 110.4 (C), 113.2 (C), 113.9 (CH), 115.8 (CH), 115.9 (C), 119.4 (CH), 119.7 (C), 120.9 (CH), 128.1 (CH), 129.4 (C), 129.6 (CH), 131.2 (CH), 132.4 (C), 145.2 (C), 152.2 (C), 153.1 (C), 159.6 (C), 179.8 (C), 183.9 (C); EIMS m/z

2	
3	
1	
4	
3 4 5 6 7 8 9 10 11	
6	
2	
7	
8	
õ	
9	
10	
44	
11	
12	
12	
13	
14	
15	
10	
16	
17	
40	
18	
19	
20	
20	
21	
22	
22	
23	
24	
<u> </u>	
25	
26	
20	
27	
28	
20	
29	
30	
24	
31	
31 32	
32 32	
31 32 33	
31 32 33 34	
31 32 33 34 35	
31 32 33 34 35	
31 32 33 34 35 36	
31 32 33 34 35 36 37	
31 32 33 34 35 36 37	
31 32 33 34 35 36 37 38	
31 32 33 34 35 36 37 38 39	
11 12 13 14 15 16 17 18 9 20 22 23 22 26 27 28 9 30 132 33 4 35 36 37 8 9 0	
40	
31 32 33 34 35 36 37 38 39 40 41	
40 41	
40 41 42	
40 41 42 43	
40 41 42 43	
40 41 42 43 44	
40 41 42 43 44 45	
40 41 42 43 44 45	
40 41 42 43 44 45 46	
40 41 42 43 44 45 46 47	
40 41 42 43 44 45 46	
40 41 42 43 44 45 46 47 48	
40 41 42 43 44 45 46 47 48 49	
40 41 42 43 44 45 46 47 48	
40 41 42 43 44 45 46 47 48 49 50	
40 41 42 43 44 45 46 47 48 49 50 51	
40 41 42 43 44 45 46 47 48 49 50 51 52	
40 41 42 43 44 45 46 47 48 49 50 51 52	
40 41 42 43 44 45 46 47 48 49 50 51 52 53	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 55 56	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 55 56	
40 41 42 43 44 45 46 47 48 49 51 52 53 55 56 57	
40 41 42 43 44 45 46 47 48 49 50 51 52 53 55 56 57 58	
40 41 42 43 44 45 46 47 48 49 51 52 53 55 56 57	

621 (M⁺, 32), 620 (16), 481 (6), 382 (16), 135 (100); HREIMS 622.1752 (calcd for $C_{34}H_{37}O_6^{81}Br 622.1753$), 620.1781 (calcd for $C_{34}H_{37}O_6^{79}Br 620.1774$). 11-bromo-2-hydroxy-6-(2-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7j). 11.4 mg (0.04 mmol) of embelin, 20 mg (0.06 mmol) of 5bromo-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 0.7 mg of EDDA (10% mol) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120°C for 10 min. The solvent was removed under vacuum and compound 7j (14.2 mg, 57%) was obtained as an amorphous brown solid after purification by preparative-TLC with 30% Hex/EtOAc as a yellow oil. IR v_{max} 3518, 3402, 2924, 2854, 1620, 1477, 1350, 1057, 972, 822, 667 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 0.87 (t, J = 6.8 Hz, 3H), 1.25 (bs, 16H), 1.49 (m, 2H), 2.49 (t, J = 7.5 Hz, 2H), 3.79 (s, 3H), 4.47 (d, J =12.9 Hz, 1H), 4.74 (d, J = 12.9 Hz, 1H), 4.85 (s, 1H), 6.69 (d, J = 8.6 Hz, 1H), 6.80 (dd, J = 1.0, 2.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.99 (td, J = 0.7, 7.5 Hz, 1H), 7.23 (dd, J= 2.4, 8.8 Hz, 1H), 7.30 (td, J = 1.5, 7.7 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂ x 2), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.67 (CH₂ x 2), 30.7 (CH), 55.7 (CH₃), 68.1 (CH₂), 109.2 (C), 110.5 (C), 111.4 (CH), 112.8 (C), 119.2 (CH), 119.5 (C), 120.1 (C), 120.8 (CH), 128.2 (CH), 129.2 (C), 130.8 (CH), 131.1 (CH), 131.7 (CH), 151.1 (C), 152.6 (C), 153.4 (C), 157.2 (C), 180.0 (C), 183.5 (C); EIMS *m/z* 622 (M⁺, 32), 620 (16), 481 (6), 382 (16), 135 (100); HRMS 622.1752 (calcd. for C₃₄H₃₇O₆⁸¹Br 622.1753), 620.1781 (calcd. for C₃₄H₃₇O₆⁷⁹Br 620.1774).

11-bromo-2-hydroxy-6-(3-hydroxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7k). 23 mg (0.08 mmol) of embelin, 40 mg (0.12 mmol) of 5bromo-2-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.4 mg of EDDA

(10 mol %) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120°C for 10 min. The solvent was removed under vacuum and compound 7k (36.6 mg, 75%) was obtained as an amorphous brown solid after purification by preparative-TLC with Hex:AcOEt 30%. Mp: 197.2-199.0 °C; IR v_{max} 3518, 3398, 3255, 3061, 2951, 2923, 2854, 1620, 1531, 1477, 1350, 1057, 968, 823, 667 cm⁻¹, H-NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.0 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.50 (t, J=7.8 Hz, 2H), 4.84 (s, 1H), 4.87 (d, J=12.4 Hz, 2H), 4.90 (d, J=12.4 Hz, 1H), 5.15 (bs, 1H), 6.72 (d, J = 8.6 Hz, 1H), 6.78 (dd, J = 1.0, 2.3 Hz, 1H), 6.90 (m, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.28 (m. 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (2 x CH₂), 30.8 (CH), 31.9 (CH₂), 67.6 (CH₂), 108.1 (C), 110.4 (C), 113.3 (C), 115.2 (CH), 117.2 (CH), 119.4 (CH), 119.7 (C), 121.0 (CH), 128.1 (CH), 129.3 (C), 129.8 (CH), 131.3 (CH), 132.5 (C), 144.9 (C), 151.1 (C), 152.1 (C), 153.1 (C), 155.7 (C), 179.9 (C), 183.3 (C); EIMS *m*/*z* 608 (M⁺, 68), 580 (20), 446 (40), 314 (44), 131 (30), 68 (100); HRMS 608.1617 (calcd for $C_{33}H_{35}O_6^{81}Br$ 608.1597), 606.1599 (calcd for $C_{33}H_{35}O_6^{79}Br$ 606.1617). 11-bromo-2-hydroxy-6-phenyl-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)dione (71). Following the general procedure described above, 25.0 mg of embelin (0.09 mmol), 40 mg (0.13 mmol) of 5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1yl)oxy)benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 28.5 mg (57 %) of 7l as an amorphous brown solid. Mp: 146.2-146.7 °C; IR (neat) v_{max} 3342, 2920, 2851, 1653, 1619, 1478, 1446, 1398, 1346, 1325, 1249, 1218, 1168, 1117, 1091, 1070, 1008, 983, 920. 861. 811 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.1 Hz, 3H), 1.26 (bs, 16H), 1.52 (m, 2H), 2.51 (t, J=7.6 Hz, 2H), 4.85 (s, 1H), 4.87 (d, J=12.7 Hz, 1H), 4.90

(d, J=13.0 Hz, 1H), 6.72 (d, J=8.8 Hz, 1H), 6.80 (s, 1H), 7.24 (d, J=1.7, 8.5 Hz, 1H), 7.41 (m, 5H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.7 (CH₂), 29.7 (CH₂), 30.8 (CH), 31.9 (CH₂), 67.7 (CH₂), 107.8 (C), 110.5 (C), 113.2 (C), 119.4 (CH), 119.7 (C), 128.1 (CH), 128.4 (CH x 2), 128.6 (CH x 2), 129.4 (C), 130.1 (CH), 131.2 (C), 131.2 (CH), 145.4 (C), 151.1 (C), 152.2 (C), 153.1 (C), 179.9 (C), 183.4 (C); EIMS *m/z* 592 (M⁺, 100), 590 (73), 451 (19), 298 (60); HREIMS 592.1650 (calcd for C₃₃H₃₅O₅⁸¹Br 592.1647), 590.1659 (calcd for C₃₃H₃₅O₅⁷⁹Br 590.1668).

11-bromo-2-hydroxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-c]chromene-

1,4(7H,12bH)-dione (7m). Following the general procedure described above, 16.3 mg (0.06 mmol) of embelin, 30 mg (0.08 mmol) of 5-chloro-2-((3-(3-nitrophenyl)prop-2yn-1-yl)oxy)benzaldehyde and 1.0 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 31.3 mg (88 %) of 7m as a yellow oil. IR (neat) v_{max} 3383, 3085, 2924, 2853, 2361, 2339, 1697, 1653, 1623, 1533, 1476, 1395, 1345, 1260, 1227, 1173, 1120, 1099, 1029, 989, 952, 908, 853, 815 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.1 Hz, 3H), 1.25 (bs, 16H), 1.52 (m, 2H), 2.51 (t, J=7.6 Hz, 2H), 4.79 (d, J=12.7 Hz, 1H), 4.88 (s, 1H), 4.97 (d, J=12.7 Hz, 1H), 6.74 (d, J=8.9 Hz, 1H), 6.80 (d, J=1.2 Hz, 1H), 7.26 (dd, J=1.9, 8.6 Hz, 1H), 7.64 (t, J=8.0 Hz, 1H), 7.76 (dt, J=1.6, 7.7 Hz, 1H), 8.23 (t, J=1.6 Hz, 1H), 8.30 (dd, J=1.3, 8.3 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (CH₂), 29.8 (CH₂), 30.9 (CH), 31.9 (CH₂), 67.2 (CH₂), 110.3 (C), 110.6 (C), 113.7 (C), 119.6 (CH), 120.0 (C), 123.4 (CH), 124.8 (CH), 128.2 (CH), 129.0 (C), 129.9 (CH), 131.5 (CH), 132.8 (C), 134.2 (CH), 143.0 (C), 148.2 (C), 151.2 (C), 151.6 (C), 152.9 (C), 179.6 (C), 183.2 (C);

EIMS m/z 636 (M⁺, 96), 635 (94), 618 (67), 501 (32), 343 (37), 149 (100); HREIMS 635.1533 (calcd for C₃₃H₃₄O₇⁷⁹BrN 635.1519), 636.1481 (calcd for C₃₃H₃₃O₇⁸¹BrN 636.1420).

11-bromo-2-hydroxy-6-(3-(trifluoromethyl)phenyl)-3-undecylchromeno[3,4-c]chromene1,4(7H,12bH)-dione (7n). Following the general procedure described above, 30.7 mg
(0.1 mmol) of embelin, 60 mg (0.16 mmol) of 5-chloro-2-((3-(3-

trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.0 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 64.5 mg (99 %) of 7n as an amorphous brown solid. Mp: 76.0-77.7 °C; IR (neat) v_{max} 3368, 2926, 2855, 2360, 2338, 1697, 1649, 1626, 1558, 1477, 1440, 1335, 1263, 1223, 1170, 1129, 1074, 1027, 989, 909, 816 cm⁻¹;¹H-NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.1 Hz, 3H), 1.25 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J=7.3 Hz, 2H), 4.79 (d, J=12.6 Hz, 1H), 4.86 (s, 1H), 4.93 (d, J=12.6 Hz, 1H), 6.72 (d, J=8.5 Hz, 1H), 6.79 (s, 1H), 7.25 (d, J=8.5 Hz, 1H), 7.58 (m, 2H), 7.64 (s, 1H), 7.70 (d, J=7.2 Hz, 1H); ¹³C-NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.2 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.7 (2xCH₂), 30.8 (CH), 31.9 (CH₂), 67.3 (CH₂), 109.4 (C), 110.5 (C), 113.5 (C), 119.5 (CH), 119.9 (C), 123.6 (C, *J*_{C-F}= 272.2Hz), 125.2 (CH, J_{C-F}=3.6 Hz), 126.8 (CH, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.6 Hz), 126.8 (CH, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), 129.3 (CH), 131.2 (C, J_{C-F}=3.2 Hz), 128.1 (CH), 129.1 (C), _F= 32.4Hz), 131.4 (CH), 131.7 (CH), 132.0 (C), 143.9 (C), 151.4 (C), 151.9 (C), 152.9 (C), 179.6 (C), 183.6 (C); EIMS *m*/*z* 614 (M⁺, 86), 596 (76), 444 (38), 320 (67), 173 (87); HREIMS 658.1522 (calcd for C₃₄H₃₄O₅⁷⁹BrF₃ 658.1542), 660.1550 (calcd for C₃₄H₃₄O₅⁸¹BrF₃ 660.1521).

2-hydroxy-6-(4-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)dione (**7o**). Following the general procedure described above, 29.4 mg (0.10 mmol) of

embelin, 40 mg (0.16 mmol) of 5-chloro-2-((3-(4-methoxyphenyl)prop-2-yn-1vl)oxy)benzaldehvde and 1.8 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 47.8 mg (88 %) of 70 as an amorphous brown solid. Mp: 124.7-126.0 °C; IR (neat) v_{max} 3341, 2924, 2854, 1687, 1650, 1607, 1513, 1485, 1452, 1403, 1355, 1304, 1249, 1223, 1175, 1113, 1085, 1023, 987, 904, 843 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.2 Hz, 3H), 1.25 (bs, 16H), 1.48 (m, 2H), 2.46 (t, J=7.5 Hz, 2H), 3.83 (s, 3H), 4.81 (s, 1H), 4.85 (d, J=12.8 Hz, 1H), 4.91 (d, J=12.8 Hz, 1H), 6.69 (d, J=7.2 Hz, 1H), 6.84 (m, 2H), 6.93 (d, J=8.8 Hz, 2H), 6.90 (d, *J*=8.2 Hz, 2H), 7.12 (t, *J*=7.1 Hz, 1H), 7.32 (d, *J*=8.2 Hz, 2H); ¹³C-NMR (500 MHz, CDCl₃) & 14.1 (CH₃), 22.7 (2x CH₂), 28.2 (CH₂), 29.4 (2 x CH₂), 29.6 (2 x CH₂), 29.7 (CH₂ x 2), 30.8 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.7 (CH₂), 107.7 (C), 111.0 (C), 113.8 (CH x 2), 117.5 (CH), 119.2 (C), 121.1 (CH), 123.8 (C), 125.2 (CH), 128.2 (C), 128.5 (CH), 128.6 (C), 129.9 (CH x 2), 132.1 (C), 144.5 (C), 153.9 (C), 160.6 (C), 180.1 (C), 183.8 (C); EIMS *m*/*z* 542 (M⁺, 82), 483 (14), 402 (16), 305 (20), 135 (100); HREIMS 542.2678 (calcd for $C_{34}H_{38}O_6$ (M⁺) 542.2668). 2-hydroxy-6-(3-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)*dione (7p)*. Following the general procedure described above, 36.8 mg of embelin (0.13) mmol), 50 mg (0.19 mmol) of 5-chloro-2-((3-(3-methoxyphenyl)prop-2-yn-1yl)oxy)benzaldehyde and 2.3 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 49.4 mg (70%) of 7p as an amorphous brown solid. Mp: 69.5-71.2 °C; ¹H NMR (500 MHz, CDCl₃) & 0.88 (t, J=7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, J=7.7 Hz, 2H), 3.82 (s, 3H), 4.83 (s, 1H), 4.86 (s, 1H), 4.89 (d, J=13.0 Hz, 1H), 4.92 (d, J=13.2 Hz, 1H), 6.72 (d, J=7.7 Hz, 1H),

ACS Paragon Plus Environment

6.84 (d, *J*=8.1 Hz, 1H), 6.88 (t, *J*=7.4 Hz, 1H), 6.96 (m, 3H), 7.15 (t, *J*=7.6 Hz, 1H), 7.31 (t, *J*=7.7 Hz, 1H); IR (neat) ν_{max} 3346, 3057, 2925, 2854, 1693, 1647, 1623, 1602, 1485, 1458, 1348, 1263, 1222, 1179, 1117, 1041, 1024, 990, 866 cm⁻¹; ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (2 x CH₂), 29.7 (CH₂), 30.8 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.6 (CH₂), 108.9 (C), 111.0 (C), 113.8 (CH), 115.7 (CH), 117.6 (CH), 119.4 (C), 120.9 (CH), 121.1 (CH), 125.2 (CH), 127.5 (C), 128.2 (CH), 129.5 (CH), 132.6 (C), 144.5 (C), 151.1 (C), 152.0 (C), 153.9 (C), 159.5 (C), 180.1 (C), 183.5 (C); EIMS *m/z* 542 (M⁺, 6), 524 (8), 387 (9), 304 (8), 135 (100); HREIMS 542.2684 (calcd for C₃₄H₃₈O₆ (M⁺) 542.2668).

2-hydroxy-6-(2-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)dione (**7q**). Following the general procedure described above, 29.4 mg (0.10 mmol) of embelin, 40 mg (0.15 mmol) of 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1yl)oxy)benzaldehyde and 1.8 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 43.4 mg (80 %) of **7q** as an amorphous brown solid. Mp: 74.3-75.5 °C; IR (neat) v_{max} 3308, 3073, 2924, 2853, 1697, 1646, 1620, 1601, 1486, 1460, 1437, 1397, 1348, 1282, 1250, 1223, 1180, 1116, 1082, 1044, 1018, 989, 863, 822 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.2 Hz, 3H), 1.26 (bs, 16H), 1.49 (m, 2H), 2.48 (t, *J*=8.0 Hz, 2H), 3.80 (s, 3H), 4.49 (d, *J*=12.8 Hz, 1H), 4.77 (d, *J*=12.8 Hz, 1H), 4.88 (s, 1H), 6.73 (d, *J*=7.5 Hz, 1H), 6.82 (d, *J*=8.4 Hz, 1H), 6.87 (t, *J*=7.5 Hz, 1H), 6.93 (d, *J*=8.4 Hz, 1H), 6.99 (t, *J*=7.5 Hz, 1H), 7.14 (t, *J*=7.5 Hz, 1H), 7.32 (dd, *J*=1.5, 7.7 Hz, 1H), 7.39 (td, *J*=1.8, 7.7 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂ x 3), 30.7 (CH), 31.9 (CH₂), 55.6 (CH₃), 67.9 (CH₂),

110.1 (C), 111.1 (C), 111.3 (CH), 117.4 (CH), 119.2 (C), 120.3 (C), 120.7 (CH), 120.8 (CH), 125.3 (CH), 127.2 (C), 128.1 (CH), 130.9 (CH), 131.5 (CH), 141.2 (C), 151.1 (C), 152.4 (C), 154.2 (C), 157.2 (C), 180.2 (C), 183.6 (C); EIMS *m/z* 542 (M⁺, 82), 483 (14), 402 (16), 305 (20), 135 (100); HREIMS 542.2678 (calcd for C₃₄H₃₈O₆ (M⁺) 542.2668).

2-hydroxy-6-(3-hydroxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)dione (7r). Following the general procedure described above, 30.0 mg (0.08 mmol) of embelin, 30 mg (0.12 mmol) of 5-chloro-2-((3-(3-hydroxyphenyl)prop-2-yn-1yl)oxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 38.1 mg (92 %) of 7r as an amorphous brown solid. Mp: 80.7-81.8 °C; IR (neat) v_{max} 3365, 2924, 2853, 2360, 2337, 1651, 1621, 1485, 1451, 1351, 1270, 1224, 1202, 1117, 1033, 993 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J=6.9 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J=7.5 Hz, 2H), 4.86 (s, 1H), 4.89 (s, 2H), 6.70 (d, J=7.4 Hz, 1H), 6.87 (m, 5H), 7.15 (t, J=7.3 Hz, 1H), 7.23 (m, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (CH₂ x 3), 29.7 (CH₂), 30.8 (CH), 31.9 (CH₂), 67.6 (CH₂), 109.0 (C), 111.1 (C), 115.3 (CH), 117.1 (CH), 117.6 (CH), 119.4 (CH), 120.8 (C), 121.2 (CH), 125.2 (CH), 127.4 (CH), 128.3 (CH), 129.7 (C), 132.6 (C), 144.3 (C), 151.9 (C), 153.9 (C), 156.0 (C), 180.4 (C), 183.4 (C); EIMS *m*/*z* 528 (M⁺, 62), 447 (37), 388 (18), 277 (100), 235 (52); HREIMS 528.2515 (calcd for $C_{33}H_{36}O_6 (M^+) 528.2512).$

2-hydroxy-6-phenyl-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (**7s**). Following the general procedure described above, 41.5 mg (0.14 mmol) of embelin, 50 mg (0.21 mmol) of 5-chloro-2-((3-phenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.5 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 53.1 mg (74 %) of 7s as an amorphous brown solid. Mp: 117.6-119.0 °C; IR (neat) v_{max} 3344, 3065, 2923, 2852, 2359, 1897, 1654, 1616, 1485, 1450, 1404, 1348, 1326, 1249, 1217, 1180, 1115, 1089, 1071, 1017, 983, 928, 863 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, *J*=7.1 Hz, 3H), 1.27 (bs, 16H), 1.51 (m, 2H), 2.50 (t, *J*=7.8 Hz, 2H), 4.87 (s, 1H), 4.89 (d, *J*=12.9 Hz, 1H), 4.93 (d, *J*=12.9 Hz, 1H), 6.72 (d, *J*=7.7 Hz, 1H), 6.85 (d, *J*=7.9 Hz, 1H), 6.88 (t, *J*=7.4 Hz, 1H), 7.15 (t, *J*=7.7 Hz, 1H), 7.41 (m, 5H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (3 xCH₂), 30.8 (CH), 31.9 (CH₂), 67.6 (CH₂), 108.7 (C), 111.0 (C), 117.5 (CH), 119.4 (C), 121.1 (CH), 125.2 (CH), 127.4 (C), 128.2 (CH), 128.4 (2 x CH), 128.5 (2 x CH), 129.8 (CH), 131.4 (C), 131.8 (C), 144.7 (C), 151.1 (C), 152.0 (C), 153.9 (C), 180.1 (C), 183.5 (C); EIMS *m*/*z* 512 (M⁺, 43), 484 (12), 372 (14), 277 (100), 262 (39); HREIMS 512.2587 (calcd for C₃₃H₃₆O₅ (M⁺) 512.2563).

2-hydroxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7t). Following the general procedure described above, 41.8 mg of embelin (0.14 mmol), 50 mg (0.21 mmol) of 5-chloro-2-((3-nitrophenyl)prop-2-yn-1yl)oxy)benzaldehyde and 2.6 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 62.2 mg (80 %) of 7t as an amorphous brown solid. Mp: 88.7-89.2 °C; IR (neat) ν_{max} 3387, 2926, 2854, 1653, 1624, 1533, 1484, 1456, 1347, 1262, 1227, 1181, 1117, 1029, 992, 950, 907, 866, 812 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, *J*=7.5 Hz, 2H), 4.80 (d, *J*=13.1 Hz, 1H), 4.90 (s, 1H), 4.99 (d, *J*=13.1 Hz,

ACS Paragon Plus Environment

1H), 6.72 (d, *J*=7.6 Hz, 1H), 6.86 (d, *J*=8.4 Hz, 1H), 6.90 (t, *J*=7.4 Hz, 1H), 7.16 (t, *J*=7.4 Hz, 1H), 7.62 (t, *J*=8.2 Hz, 1H), 7.77 (dt, *J*=1.4, 7.6Hz, 1H), 8.25 (t, *J*=1.7 Hz, 1H), 8.28 (dd, *J*=1.4, 8.3 Hz, 1H); ¹³C NMR (500 MHz,CDCl₃) δ 14.1 (CH₃), 22.7 (2xCH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (2xCH₂), 29.7 (CH₂), 30.9 (CH), 31.9 (CH₂), 67.1 (CH₂), 111.2 (C), 111.3 (C), 117.7 (CH), 119.6 (C), 121.5 (CH), 123.4 (CH), 124.6 (CH), 125.2 (CH), 127.2 (C), 128.5 (CH), 129.7 (CH), 133.0 (C), 134.2 (CH), 142.3 (C), 148.1 (C), 151.2 (C), 151.5 (C), 153.7 (C), 179.8 (C), 183.3 (C); EIMS *m*/*z* 557 (M⁺, 100), 512 (28), 416 (38), 388 (31), 264 (56); HREIMS 557.2440 (calcd for C₃₃H₃₅O₇N (M⁺) 557.2414).

2-hydroxy-6-(3-(trifluoromethyl)phenyl)-3-undecylchromeno[3,4-c]chromene-

1,4(7H,12bH)-dione (7u). Following the general procedure described above, 32.2 mg (0.11 mmol) of embelin, 50 mg (0.16 mmol) of 5-chloro-2-((3-(3-

trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 2.6 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 51.1 mg (88 %) of **7u** as a yellow oil. IR (neat) v_{max} 3347, 3071, 2925, 2854, 2361, 2338, 1695, 1648, 1624, 1485, 1457, 1399, 1335, 1259, 1221, 1169, 1127, 1073, 1027, 992, 909, 865, 810 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.1 Hz, 3H), 1.26 (bs, 16H), 1.51 (m, 2H), 2.50 (t, *J*=7.6 Hz, 2H), 4.80 (d, *J*=12.7 Hz, 1H), 4.90 (s, 1H), 4.96 (d, *J*=13.0 Hz, 1H), 6.72 (d, *J*=7.7 Hz, 1H), 6.86 (d, *J*=8.4 Hz, 1H), 6.90 (d, *J*=7.7 Hz, 1H), 7.17 (t, *J*=7.7 Hz, 1H), 7.56 (t, *J*=7.8 Hz, 1H), 7.61 (d, *J*=7.5 Hz, 1H), 7.66 (s, 1H), 7.69 (d, *J*=7.5 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂

 J_{C-F} =3.6 Hz), 127.2 (C), 128.4 (CH), 129.1 (CH), 131.1 (C, J_{C-F} = 33.0Hz), 131.7 (CH), 132.2 (C), 143.2 (C), 151.1 (C), 151.7 (C), 153.7 (C), 179.9 (C), 183.4 (C); EIMS *m/z* 580 (M⁺, 28), 423 (26), 359 (25), 315 (20), 172 (100); HREIMS 580.2461 (calcd for C₃₄H₃₅O₅F₃ (M⁺) 580.2437).

2-hydroxy-10-methoxy-6-(4-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7v). Following the general procedure described above, 26.5 mg (0.09 mmol) of embelin, 40 mg (0.14 mmol) of 5-chloro-2-((3-(4-methoxyphenyl)prop-2-vn-1-vl)oxy)benzaldehvde and 1.6 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 42.5 mg (82 %) of 7v as an amorphous brown solid. Mp: 143.1-145.1 °C; IR (neat) v_{max} 3517, 3398, 3348, 2925. 2853, 1613, 1501, 1464, 1357, 1303, 1061, 972 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J=7.0 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.48 (t, J=7.7 Hz, 2H), 3.74 (s, 3H), 3.83 (s, 3H), 4.84 (m, 2H), 4.88 (d, J=12.5 Hz, 1H), 6.39 (d, J=2.3 Hz, 1H), 6.43 (dd, J=2.3, 8.6 Hz, 1H), 6.62 (d, J=8.6 Hz, 1H), 6.93 (d, J=8.6 Hz, 2H), 7.28 (s, 1H), 7.35 (d, J=8.8 Hz, 2H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (2 x CH₂), 29.7 (CH₂), 30.4 (CH), 31.9 (CH₂), 55.3 (CH₃), 55.4 (CH₃), 67.6 (CH₂), 102.8 (CH), 107.3 (CH), 107.5 (C), 111.5 (C), 113.9 (CH x 2), 119.3 (C), 119.5 (C), 123.8 (C), 126.0 (CH), 130.0 (CH x 2), 144.8 (C), 151.1 (C), 152.0 (C), 154.8 (C), 159.8 (C), 160.7 (C), 180.2 (C), 183.7 (C); EIMS *m/z* 572 (M⁺, 1), 452 (3), 336 (14), 296 (17), 145 (100); HREIMS 572.2747 (calcd for $C_{35}H_{40}O_7$ (M⁺) 572.2774).

2-hydroxy-10-methoxy-6-(3-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7w). Following the general procedure described above, 19.8 mg (0.07 mmol) of embelin, 30 mg (0.10 mmol) of 5-chloro-2-((3-(3-methoxyphenyl)prop-

2-yn-1-yl)oxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 27.7 mg (72 %) of 7w as an amorphous brown solid. Mp: 88.2-89.4° C; IR (neat) v_{max} 3314, 2924, 2853, 1361, 2338, 1694, 1617, 1500, 1461, 1435, 1347, 1255, 1210, 1160, 1118, 1081, 1029, 930, 838 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.1 Hz, 3H), 1.25 (bs, 16H), 1.49 (m, 2H), 2.48 (t, J=7.6 Hz, 2H), 3.73 (s, 3H), 3.82 (s, 3H), 4.83 (s, 1H), 4.84 (d, J=12.1 Hz, 1H), 4.90 (d, J=12.7 Hz, 1H), 6.39 (d, J=2.5 Hz, 1H), 6.43 (dd, J=2.4, 8.5 Hz, 1H), 6.62 (d, J=8.7 Hz, 1H), 6.96 (m, 3H), 7.32 (td, J=1.4, 7.6 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) & 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂ x 2), 29.7 (CH₂), 30.4 (CH), 31.9 (CH₂), 55.3 (CH₃), 55.4 (CH₃), 67.5 (CH₂), 102.8 (CH), 107.3 (CH), 108.7 (C), 111.4 (C), 113.9 (CH), 115.7 (CH), 119.3 (C), 119.4 (C), 121.0 (CH), 126.0 (CH), 129.5 (CH), 132.6 (C), 144.7 (C), 151.1 (C), 151.9 (C), 154.8 (C), 159.6 (C), 159.8 (C), 180.1 (C), 183.6 (C); EIMS *m/z* 572 (M⁺, 27), 554 (100), 413 (13), 279 (12), 135 (92); HREIMS 572.2761 (calcd for C₃₅H₄₀O₇ (M⁺) 572.2774).

2-hydroxy-10-methoxy-6-(2-methoxyphenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7x). Following the general procedure described above, 24.5 mg (0.08 mmol) of embelin, 40 mg (0.13 mmol) of 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.5 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 23.6 mg (50%) of 7x as a yellow oil. IR (neat) v_{max} 3312, 2924, 2852, 1706, 1600, 1496, 1460, 1437, 1348, 1281, 1248, 1162, 1116, 1019, 933, 834 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.1 Hz, 3H), 1.25 (bs, 16H), 1.48 (m, 2H), 2.46 (t, *J*=6.9 Hz, 2H), 3.73 (s, 3H), 3.80 (s, 3H), 4.47 (d, *J*=12.6 Hz, 1H), 4.70 (d, *J*=12.6 Hz, 1H), 4.84 (s, 1H), 6.36 (s, 1H), 6.32 (d, J=2.0 Hz, 1H), 6.63 (d, J=8.0 Hz, 1H), 6.93 (d, J=8.3 Hz, 1H), 6.98 (t, J=7.5 Hz, 1H), 7.33 (dd, *J*=1.1, 7.3 Hz, 1H), 7.38 (m, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (2 x CH₂), 29.7 (CH₂), 30.3 (CH), 31.9 (CH₂), 55.3 (CH₃), 55.7 (CH₃), 67.9 (CH₂), 99.7 (C), 102.6 (CH), 106.9 (CH), 109.9 (C), 111.4 (CH), 119.2 (C), 119.3 (C), 120.3 (C), 120.7 (CH), 126.1 (CH), 131.0 (CH), 131.5 (CH), 141.3 (C), 151.1 (C), 152.4 (C), 155.1 (C), 157.2 (C), 159.7 (C), 180.3 (C), 183.7 (C); EIMS *m/z* 572 (M⁺, 19), 452 (13), 335 (29), 135 (100); HREIMS 572.2755 (calcd for C₃₅H₄₀O₇ (M⁺) 572.2774). 2-hydroxy-6-(3-hydroxyphenyl)-10-methoxy-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7y). Following the general procedure described above, 27.8 mg (0.09 mmol) of embelin, 40 mg (0.14 mmol) of 5-chloro-2-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.7 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 40.0 mg (76%) of 7y as an amorphous brown solid. Mp: 160.2-161.4 °C; IR (neat) v_{max} 3514, 3397, 2923, 2852, 1617, 1500, 1443, 1349, 1154, 1113, 1076, 971 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J=7.1 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J=7.7 Hz, 2H), 3.74 (s, 3H), 4.82 (m, 2H), 4.89 (d, J=12.7 Hz, 1H), 5.35 (bs, 1H), 6.39 (s, 1H), 6.44 (dd, J=1.8, 8.6 Hz, 1H), 6.61 (d, J=8.4 Hz, 1H), 6.88 (m, 2H), 6.93 (d, J=7.5 Hz, 1H), 7.24 (m, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.7 (2 x CH₂), 28.1 (CH₂), 29.4 (2 x CH₂), 29.6 (3 x CH₂), 29.7 (CH₂), 30.4 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.5 (CH₂), 102.8 (CH), 107.4 (CH), 108.8 (C), 111.5 (C), 115.4 (CH), 116.5 (C), 110.1 (CH), 119.3 (C), 121.0 (CH), 126.0 (CH), 129.7 (CH), 132.7 (C), 144.5 (C), 151.2 (C), 151.9 (C), 154.8

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27 28	
28	
29	
30	
31	
32	
33	
34 35	
35	
36	
37 38	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

(C), 155.7 (C), 159.8 (C), 180.3 (C), 183.6 (C); EIMS *m*/*z* 558 (M⁺, 1), 282 (14), 254 (18), 131 (100); HREIMS 558.2609 (calcd for $C_{34}H_{38}O_7$ (M⁺) 558.2618). 2-hydroxy-10-methoxy-6-phenyl-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)*dione (7z)*. Following the general procedure described above, 36.8 mg (0.13 mmol) of embelin, 50 mg (0.19 mmol) of 5-chloro-2-((3-phenyl)prop-2-yn-1yl)oxy)benzaldehyde and 2.3 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 62.4 mg (92%) of 7z as an amorphous brown solid. Mp: 151.0-151.8 °C; IR (neat) v_{max} 3340, 2923, 2853, 2359, 1652, 1615, 1578, 1497, 1444, 1351, 1317, 1253, 1241, 1218, 1157, 1119, 1019, 997, 928, 903, 849 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=6.9 Hz, 3H), 1.26 (bs, 16H), 1.50 (m, 2H), 2.49 (t, *J*=7.4 Hz, 2H), 3.74 (s, 3H), 4.86 (m, 3H), 6.39 (s, 1H), 6.44 (d, J=8.0 Hz, 1H), 6.63 (d, J=8.2 Hz, 1H), 7.42 (m, 5H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂ x 2), 29.7 (CH₂), 30.4 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.5 (CH₂), 102.8 (CH), 107.3 (CH), 108.5 (C), 111.5 (C), 119.3 (C), 119.4 (C), 126.1 (CH), 128.4 (CH x 2), 128.5 (CH x 2), 129.9 (CH), 131.4 (C), 151.1 (C), 151.9 (C), 154.7 (C), 159.8 (C), 180.2 (C), 183.7 (C); EIMS m/z 542 (M⁺, 100), 528 (22), 402 (33), 262 (40), 249 (58); HREIMS 542.2643 (calcd for $C_{34}H_{38}O_6$ (M⁺) 542.2668). 2-hydroxy-10-methoxy-6-(3-nitrophenyl)-3-undecylchromeno[3,4-c]chromene-1,4(7H,12bH)-dione (7aa). Following the general procedure described above, 22.0 mg of embelin (0.08 mmol), 35 mg (0.11 mmol) of 5-chloro-2-((3-nitrophenyl)prop-2-yn-1yl)oxy)benzaldehyde and 2.3 mg of EDDA (10 mol %) were suspended in 2 mL of

DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 27.2 mg (62%) of **7aa** as an

amorphous brown solid. Mp: 93.3-95.0 °C; IR (neat) v_{max} 3384, 3055, 2927, 2854, 2360, 1655, 1622, 1534, 1502, 1463, 1441, 1350, 1264, 1227, 1191, 1161, 1121, 1098, 1030, 951, 899, 840, 812 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, *J*=7.1 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J=7.5 Hz, 2H), 3.74 (s, 3H), 4.79 (d, J=12.5 Hz, 1H), 4.87 (s, 1H), 4.91 (d, J=13.0 Hz, 1H), 6.41 (d, J=1.9 Hz, 1H), 6.46 (dd, J=1.9, 8.3 Hz, 1H), 6.63 (d, J=8.5 Hz, 1H), 7.63 (t, J=8.1 Hz, 1H), 7.78 (d, J=7.7 Hz, 1H), 8.26 (s, 1H), 8.29 (d, *J*=8.3 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 22.6 (CH₂), 22.7 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (2xCH₂), 30.5 (CH), 31.9 (CH₂), 55.4 (CH₃), 67.0 (CH₂), 102.9 (CH), 107.8 (CH), 111.0 (C), 111.6 (C), 119.0 (C), 119.6 (C), 123.5 (CH), 124.6 (CH), 126.1 (CH), 129.8 (CH), 133.1 (C), 134.4 (CH), 132.9 (C), 142.5 (C), 148.2 (C), 151.2 (C), 151.4 (C), 154.6 (C), 159.9 (C), 179.8 (C), 183.5 (C); EIMS *m/z* 587 (M⁺, 21), 569 (100), 540 (20), 452 (16), 294 (17), 166 (51); HREIMS 587.2530 (calcd for $C_{34}H_{37}O_8N$ (M⁺) 587.2519). 2-hydroxy-10-methoxy-6-(3-(trifluoromethyl)phenyl)-3-undecylchromeno[3,4c]chromene-1,4(7H,12bH)-dione (7ab). Following the general procedure described above, 17.6 mg (0.06 mmol) of embelin, 30 mg (0.09 mmol) of 4-methoxy-2-((3-(3trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzaldehyde and 1.1 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 14.0 mg (38%) of **7ab** as a yellow oil. IR (neat) v_{max} 3346, 2925, 2854, 2359, 1651, 1618, 1501, 1461, 1440, 1336, 1248, 1221, 1165, 1074, 1030, 909, 838, 808 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.87 (t, J=7.0 Hz, 3H), 1.25 (bs, 16H), 1.50 (m, 2H), 2.49 (t, J=7.6 Hz, 2H), 3.74 (s, 1H), 4.79 (d, J=12.5 Hz, 1H), 4.86 (s, 1H), 4.89 (d, J=12.8 Hz, 1H), 6.41 (d, J=1.5 Hz, 1H), 6.45 (d, J=7.7 Hz, 1H), 6.63 (d, J=8.5, 1H), 7.57 (t, J=7.6 Hz, 1H), 7.62 (d, *J*=7.6 Hz, 1H), 7.66 (s, 1H), 7.69 (d, *J*=7.6 Hz, 1H); ¹³C NMR (500

1 2	
2 3 4 5 6 7	
6 7 8	
9 10 11	
12 13 14	
15 16 17	
18 19 20	
21 22 23	
24 25 26	
27 28 29 20	
30 31 32	
$ 8 \\ 9 \\ $	
37 38 39	
40 41 42	
43 44 45	
46 47 48	
49 50 51	
52 53 54	
55 56 57	
58 59 60	

614 (M⁺, 67), 586 (16), 473 (9), 321 (20), 135 (100); HREIMS 614.2898 (calcd for C₃₇H₄₂O₈ (M⁺) 614.2880).

ethyl 11-hydroxy-7-(3-methoxyphenyl)-9,12-dioxo-10-undecyl-6,9,12,12btetrahydrochromeno[3,4-c]chromene-3-carboxylate (7ad). Following the general procedure described above, 17.4 mg (0.06 mmol) of embelin, 30 mg (0.09 mmol) of ethyl 4-formyl-3-((3-(3-methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 1.1 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 23.9 mg (66%) of 7ad as a yellow oil. IR (neat) v_{max} 2924, 2854, 1708, 1650, 1609, 1462, 1277, 1249, 1176, 1115, 868, 768, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, J=7.1 Hz, 3H), 1.27 (bs, 16H), 1.34 (t, J=7.1 Hz, 3H), 1.53 (m, 2H), 2.51 (t, J=7.5 Hz, 2H), 3.82 (s, 3H), 4.31 (q, J=7.1 Hz, 2H), 4.87 (s, 1H), 4.91 (d, J=13.1 Hz, 1H), 4.98 (d, J=12.7 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 6.97 (m, 3H), 7.32 (t, J=7.7 Hz, 1H), 7.45 (s, 1H), 7.84 (d, J=8.4 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.0 (CH₃), 14.3 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (CH₂ x 2), 31.0 (CH), 31.9 (CH₂), 55.5 (CH₃), 60.7 (CH₂), 68.0 (CH₂), 107.7 (C), 111.0 (C), 114.2 (CH), 116.0 (CH), 117.5 (CH), 119.8 (C), 121.1 (CH), 123.5 (C), 126.9 (C), 127.7 (CH), 129.6 (CH), 130.1 (CH), 132.5 (C), 145.7 (C), 151.3 (C), 152.1 (C), 158.1 (C), 159.9 (C), 166.1 (C), 179.9 (C), 183.6 (C); EIMS m/z 614 (M⁺, 18), 584 (13), 459 (5), 377 (14), 350 (12), 135 (100); HREIMS 614.2865 (calcd for $C_{37}H_{42}O_8$ (M⁺) 614.2880).

ethyl 11-hydroxy-7-(2-methoxyphenyl)-9,12-dioxo-10-undecyl-6,9,12,12b-tetrahydro chromeno[3,4-c]chromene-3-carboxylate (7ae). Following the general procedure described above, 12.0 mg of embelin (0.04 mmol), 20 mg (0.06 mmol) of ethyl 4-formyl-3-((3-(2-methoxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 0.7 mg of EDDA (10

mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10
min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to
provide 16.0 mg (67%) of 7ae as a yellow oil. IR (neat) ν_{max} 2924, 2854, 1708, 1639,
1609, 1462, 1350, 1277, 1246, 1176, 1115, 1018, 841, 756, 659 cm ⁻¹ ; ¹ H NMR (500
MHz, CDCl ₃) δ 0.89 (t, <i>J</i> =7.0 Hz, 3H), 1.27 (bs, 16H), 1.34 (t, <i>J</i> =7.1 Hz, 3H), 1.52 (m,
2H), 2.50 (t, J=7.6 Hz, 2H), 3.79 (s, 3H), 4.31 (q, J=7.2 Hz, 2H), 4.56 (d, J=12.3 Hz,
1H), 4.78 (d, J=12.3 Hz, 1H), 4.89 (s, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.95 (d, J=8.7 Hz,
1H), 6.99 (t, J=7.6 Hz, 1H), 7.30 (dd, J=1.5, 7.6 Hz, 1H), 7.39 (m, 1H), 7.46 (s, 1H),
7.83 (dd, J=1.5, 8.6 Hz, 1H); ¹³ C NMR (500 MHz, CDCl ₃) δ 14.0 (CH ₃), 14.3 (CH ₃),
22.7 (CH ₂), 22.8 (CH ₂), 28.1 (CH ₂), 29.3 (CH ₂), 29.4 (CH ₂), 29.6 (CH ₂), 29.7 (CH ₂ x
3), 30.9 (CH), 31.9 (CH ₂), 55.9 (CH ₃), 60.7 (CH ₂), 68.5 (CH ₂), 109.0 (C), 111.0 (C),
111.8 (CH), 117.3 (CH), 119.6 (C), 120.5 (C), 120.9 (CH), 123.2 (C), 126.8 (C), 127.8
(CH), 130.0 (CH), 131.0 (CH), 131.7 (CH), 142.3 (C), 151.3 (C), 152.6 (C), 157.5 (C),
158.4 (C), 166.2 (C), 180.0 (C), 183.8 (C); EIMS <i>m/z</i> 614 (M ⁺ , 20), 570 (15), 459 (13),
377 (25), 135 (100); HREIMS 614.2858 (calcd for $C_{37}H_{42}O_8$ (M ⁺) 614.2880).
ethyl 11-hydroxy-7-(3-hydroxyphenyl)-9,12-dioxo-10-undecyl-6,9,12,12b-
tetrahydrochromeno[3,4-c]chromene-3-carboxylate (7af). Following the general
procedure described above, 12.1 mg (0.04 mmol) of embelin, 20 mg (0.06 mmol) of
ethyl 4-formyl-3-((3-(3-hydroxyphenyl)prop-2-yn-1-yl)oxy)benzoate and 0.8 mg of
EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was
irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30%
Hex/ EtOAc to provide 13.8 mg (56%) of 7af as a yellow oil; IR (neat) v_{max} 3391, 2920,
2854, 1693, 1655, 1624, 1492, 1393, 1354, 1258, 1176, 1115, 960, 872, 825, 764, 660
cm ⁻¹ ; ¹ H NMR (500 MHz, CDCl ₃) δ 0.87 (t, <i>J</i> =7.0 Hz, 3H), 1.25 (bs, 16H), 1.34 (t,
<i>J</i> =7.0 Hz, 3H), 1.50 (m, 2H), 2.49 (t, <i>J</i> =8.0 Hz, 2H), 4.32 (q, <i>J</i> =7.2 Hz, 2H), 4.87 (s,

1H), 4.89 (d, *J*=12.8 Hz, 1H), 4.97 (d, *J*=12.8 Hz, 1H), 6.83 (d, *J*=8.5 Hz, 1H), 6.88 (m, 3H), 7.24 (m, 1H), 7.42 (t, *J*=1.2 Hz, 1H), 7.83 (dd, *J*=1.7, 8.5 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.1 (CH₃), 14.3 (CH₃), 22.7 (2 x CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (2xCH₂), 30.8 (CH), 31.9 (CH₂), 60.9 (CH₂), 67.5 (CH₂), 107.4 (C), 110.8 (C), 115.3 (CH), 117.3 (CH), 117.5 (CH), 119.6 (CH), 120.8 (C), 123.1 (C), 126.6 (C), 127.6 (CH), 129.8 (CH), 130.1 (CH), 132.3 (C), 145.3 (C), 151.4 (C), 151.9 (C), 155.9 (C), 157.9 (C), 166.3 (C), 180.2 (C), 183.4 (C); EIMS *m/z* 558 (M⁺, 1), 282 (14), 254 (18), 131 (100); HREIMS 558.2609 (calcd for C₃₄H₃₈O₇ (M⁺) 558.2618).

ethyl 11-hydroxy-9, 12-dioxo-7-phenyl-10-undecyl-6, 9, 12, 12b-tetrahydrochromeno[3,4c]chromene-3-carboxylate (**7ag**). Following the general procedure described above, 19.1 mg (0.04 mmol) of embelin, 30 mg (0.10 mmol) of ethyl 4-formyl-3-((3-(3phenyl))prop-2-yn-1-yl)oxy)benzoate and 1.2 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 30.3 mg (80%) of **7ag** as an oil. IR (neat) v_{max} 2924, 2845, 1709, 1655, 1620, 1450, 1350, 1288, 2346, 1177, 1115, 1018, 983, 841, 767, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.89 (t, *J*=7.1 Hz, 3H), 1.28 (bs, 16H), 1.35 (t, *J*=7.1 Hz, 3H), 1.54 (m, 2H), 2.52 (t, *J*=7.8 Hz, 2H), 4.31 (q, *J*=7.0 Hz, 2H), 4.90 (s, 1H), 4.92 (d, *J*=13.2 Hz, 1H), 4.96 (d, *J*=12.4 Hz, 1H), 6.84 (d, *J*=8.5 Hz, 1H), 7.42 (m, 6H), 7.84 (dd, *J*=1.5, 8.5 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.0 (CH₃), 14.3 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (2 x CH₂), 29.7 (2 x CH₂), 30.0 (CH), 31.9 (CH₂), 60.7 (CH₂), 68.0 (CH₂), 107.5 (C), 111.0 (C), 117.5 (CH), 119.8 (C), 123.5 (C), 126.8 (C), 127.7 (CH), 128.6 (CH x 4), 130.1 (CH x 2), 131.4 (C), 145.9 (C), 151.3 (C), 152.2 (C), 158.0

2	
3	
4	
5	
4 5 6	
6	
7	
8	
à	
10	
10	
11	
12	
13	
10	
14	
15	
16	
17	
10	
18	
8 9 10 11 12 13 14 15 16 17 18 19 20	
20	
21	
20 21 22 23 24 25 26 27 28 29 30 31	
22	
23	
24	
25	
20	
26	
27	
28	
20	
20	
30	
31	
31 32 33 34 35	
33	
24	
34	
35	
36 37 38 39	
37	
20	
38	
39	
40	
41	
42	
42	
43	
44	
45	
46	
40	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

(C), 166.1 (C), 179.9 (C), 183.6 (C); EIMS *m/z* 584 (M⁺, 86), 540 (28), 443 (19), 291 (45), 105 (100); HREIMS 584.2747 (calcd for $C_{36}H_{40}O_7$ (M⁺) 584.2774). ethyl 11-hydroxy-7-(3-nitrophenyl)-9,12-dioxo-10-undecyl-6,9,12,12btetrahydrochromeno[3,4-c]chromene-3-carboxylate (7ah). Following the general procedure described above, 16.6 mg (0.04 mmol) of embelin, 30 mg (0.085 mmol) of ethyl 4-formyl-3-((3-(3-nitrophenyl)prop-2-yn-1-yl)oxy)benzoate and 1.1 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 28.8 mg (82%) of **7ah** as an oil; IR (neat) v_{max} 3379, 2924, 2854, 1709, 1654, 1623, 1531, 1477, 1389, 1288, 1245, 1177, 1119, 1026, 984, 856, 787, 768, 690 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.0 Hz, 3H), 1.27 (bs, 16H), 1.35 (t, *J*=7.1 Hz, 3H), 1.54 (m, 2H), 2.53 (t, J=7.8 Hz, 2H), 4.32 (q, J=7.2 Hz, 2H), 8.87 (d, J=12.8 Hz, 1H), 4.94 (s, 1H), 4.99 (d, J=12.8 Hz, 1H), 8.87 (d, J=8.6 Hz, 1H), 7.46 (t, J=1.5 Hz, 1H), 7.64 (t, J=8.2 Hz, 1H), 7.77 (d, J=7.8 Hz, 1H), 7.86 (dd, J=1.7, 8.5 Hz, 1H), 8.25 (t, J=1.7 Hz, 1H), 8.30 (d, J=8.4 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.0 (CH₃), 14.3 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.5 (CH₂), 29.6 (CH₂), 29.7 (2 x CH₂), 31.1 (CH), 31.9 (CH₂), 60.8 (CH₂), 67.5 (CH₂), 109.9 (C), 111.1 (C), 117.6 (CH), 120.1 (C), 123.6 (CH), 123.9 (C), 124.8 (CH), 126.5 (C), 127.7 (CH), 129.9 (CH), 130.3 (CH), 133.0 (C), 134.3 (CH), 143.5 (C), 148.5 (C), 151.3 (C), 151.6 (C), 157.7 (C), 166.0 (C), 179.6 (C), 183.4 (C); EIMS *m/z* 587 (M⁺, 21), 569 (100), 540 (20), 452 (16), 294 (17), 166 (51); HREIMS 587.2530 (calcd for C₃₄H₃₇O₈N (M⁺) 587.2519).

ethyl 11-hydroxy-9,12-dioxo-7-(3-(trifluoromethyl)phenyl)-10-undecyl-6,9,12,12btetrahydrochromeno[3,4-c]chromene-3-carboxylate (**7ai**). Following the general procedure described above, 20.8 mg (0.07 mmol) of embelin, 40 mg (0.11 mmol) of

ethyl 4-formyl-3-((3-(3-trifluoromethylphenyl)prop-2-yn-1-yl)oxy)benzoate and 1.3 mg of EDDA (10 mol %) were suspended in 2 mL of DCE. The reaction mixture was irradiated for 10 min at 120 °C. The crude was purified by preparative-TLC with 30% Hex/ EtOAc to provide 28.8 mg (82%) of **7ai** as an oil. IR (neat) v_{max} 2928, 2854, 1709, 1639, 1616, 1477, 1335, 1288, 1246, 1169, 1123, 1072, 1026, 987, 910, 845, 810, 767, 698 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.88 (t, *J*=7.0 Hz, 3H), 1.35 (t, *J*=7.1 Hz, 3H), 1.27 (bs, 16H), 1.54 (m, 2H), 2.52 (t, J = 7.8 Hz, 2H), 4.32 (q, J = 7.1 Hz, 2H), 4.87 (d, J = 12.7 Hz, 1H), 4.92 (s, 1H), 4.96 (d, J = 13.0 Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 7.46 (s, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.62 (d, J = 7.8, 1H), 7.66 (s, 1H), 7.71 (d, J = 7.5 Hz, 1H), 7.85 (dd, J=1.4, 8.6 Hz, 1H); ¹³C NMR (500 MHz, CDCl₃) δ 14.0 (CH₃), 14.3 (CH₃), 22.7 (CH₂), 22.8 (CH₂), 28.1 (CH₂), 29.3 (CH₂), 29.4 (CH₂), 29.6 (CH₂), 29.6 (CH₂), 29.7 (CH₂ x 2), 31.0 (CH), 31.9 (CH₂), 60.8 (CH₂), 67.6 (CH₂), 109.1 (C), 111.1 (C), 117.6 (CH), 119.6 (C), 123.7 (C, J_{C-F}= 269.7 Hz), 123.8 (C), 125.5 (CH, J_{C-F}=3.6 Hz), 126.6 (C), 126.6 (C), 126.9 (CH, J_{C-F}=3.0 Hz), 127.8 (CH), 129.3 (CH), 130.2 (CH), 131.9 (CH), 132.2 (C), 144.4 (C), 151.4 (C), 151.8 (C), 157.8 (C), 166.0 (C), 179.7 (C), 183.5 (C); EIMS m/z 652 (M⁺, 63), 608 (43), 512 (21), 415 (30), 360 (38), 173 (100); HREIMS 652.2616 (calcd for $C_{37}H_{39}O_7F_3$ (M⁺) 652.2648). 11-chloro-6-(4-methoxyphenyl)-3,4,7,12b-tetrahydrochromeno[3,4-c]chromen-1(2H)one (14). 7.5 mg (0.07 mmol) of 1,3-cyclohexanedione, 30 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120°C for 10 min. The solvent was removed under vacuum and compound 14 (23.2 mg, 87%) was obtained as an amorphous with solid after purification by preparative-TLC with 30% Hex/EtOAc. Mp: 109.4-110.6 °C; ¹H-NMR (500 MHz, CDCl₃) & 2.15 (m, 2H), 2.58 (m, 2H), 2.62 (m, 1H), 2.74 (m, 1H), 3.83 (s, 3H), 4.66 (s, 1H), 4.81 (d, J=12.2 Hz, 1H), 4.84 (d, J=

ACS Paragon Plus Environment

12.4 Hz, 1H), 6.69 (d, <i>J</i> =8	.6 Hz, 1H), 6.71 (dd, <i>J</i> =1.2, 2.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.8 Hz,
1H), 7.04 (ddd, <i>J</i> = 0.8, 2.6	, 8.6 Hz, 1H), 7.28 (d, <i>J</i> =8.8 Hz, 1H); ¹³ C-NMR (125 MHz,
CDCl ₃) δ 20.0 (CH ₂), 27.9	(CH ₂), 30.2 (CH), 36.9 (CH ₂), 55.4 (CH ₃), 67.9 (CH ₂), 107.5
(C), 109.8 (C), 113.8 (2 x (CH), 118.3 (CH), 124.4 (C), 125.5 (C), 125.7 (CH), 127.5
(CH), 129.8 (2 x CH), 130	.2 (C), 144.6 (C), 152.6 (C), 160.5 (C), 168.7 (C), 198.3 (C);
EIMS <i>m/z</i> 394 (M ⁺ , 10), 39	93 (11), 362 (6), 274 (11), 135 (100); HREIMS 394.0978
(calcd. for $C_{23}H_{19}O_4^{35}Cl 3$	94.0972), 396.0926 (calcd. for $C_{23}H_{19}O_4^{37}C1$ 396.0942).
11-chloro-6-(4-methoxyph	enyl)-3,3-dimethyl-3,4,7,12b-tetrahydrochromeno[3,4-
c]chromen-1(2H)-one (15)	. 10 mg (0.07 mmol) of dimedone, 20 mg (0.1 mmol) of 5-
chloro-2-(prop-2-yn-1-yloz	xy)benzaldehyde and 1.2 mg of EDDA (10 mol % mol) were
dissolved in 2 mL of DCE.	The reaction mixture was irradiated at 120°C for 10 min.
The solvent was removed	under vacuum and compound 15 (28.6 mg, 94%) was
obtained as an amorphous	withe solid after purification by preparative-TLC with 30%
n-hexanes:AcOEt. Mp: 11	6.0-117.4 °C; IR (neat) v _{max} 2959, 1678, 1601, 1512, 1477,
1373, 1254, 1169, 1026, 9	10, 787, 729, 648 cm ⁻¹ ; ¹ H-NMR (500 MHz, CDCl ₃) δ 1.17
(s, 1H), 1.24 (s, 1H), 2.42	(m, 2H), 2.49 (m, 1H), 2.56 (m, 1H), 3.83 (s, 3H), 4.66 (s,
1H), 4.81 (d, <i>J</i> =12.2 Hz, 1	H), 4.84 (d, <i>J</i> = 12.4 Hz, 1H), 6.69 (d, <i>J</i> =8.6 Hz, 1H), 6.71
(dd, <i>J</i> =1.2, 2.6 Hz, 1H), 6.	92 (d, J= 8.8 Hz, 1H), 7.03 (dd, J= 2.5, 8.7 Hz, 1H), 7.27 (d,
<i>J</i> =8.8 Hz, 1H); ¹³ C-NMR ((125 MHz, CDCl ₃) δ 27.7 (CH ₃), 29.3 (CH ₃), 30.3 (CH), 41.5
(CH ₂), 50.9 (CH ₂), 55.4 (C	CH ₃), 67.9 (CH ₂), 107.3 (C), 108.7 (C), 113.8 (2 x CH), 118.3
(CH), 124.4 (C), 125.5 (C)	, 125.8 (CH), 127.5 (CH), 129.7 (CH x 2), 130.6 (C), 144.7
(C), 152.4 (C), 160.4 (C),	166.9 (C), 198.3 (C); EIMS <i>m/z</i> 424 (M ⁺ , 48), 421 (100), 391
(62), 338 (18), 295 (19), 13	35 (44); HREIMS 424.1271 (calcd. for C ₂₅ H ₂₃ O ₄ ³⁷ Cl
424.1255), 422.1310 (calco	d. for $C_{25}H_{23}O_4^{35}Cl$ 422.1285).

11-chloro-6-(4-methoxyphenyl)-7,12b-dihydrochromeno[4',3':4,5]pyrano[2,3*d*]*pyrimidine-1,3(2H,4H)-dione* (**16**). 5.6 mg (0.044 mmol) of barbituric acid, 20 mg (0.07 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 0.8 mg of EDDA (10% mol) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120 ^oC for 10 min. The solvent was removed by filtration and washed with n-hexane. Compound 16 (19.1 mg, 89%) was obtained as a withe solid. Mp: 275.2-277.0 °C; IR (neat) v_{max} 3233, 3113, 2912, 2824, 1690, 1582, 1474, 1373, 1350, 1285, 1027, 1049, 852, 764, 675 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.80 (s, 3H), 4.66 (m, 2H), 4.99 (bs, 1H), 5.02 (d, J= 12.2 Hz, 1H), 6.80 (d, J=8.6 Hz, 1H), 7.05 (m, 3H), 7.16 (dd, J= 2.0, 8.3 Hz, 1H), 7.36 (d, *J*=8.7 Hz, 1H); ¹³C-NMR (150 MHz, CDCl₃) δ 30.9 (CH), 55.8 (CH₃), 67.6 (CH₂), 84.3 (C), 107.5 (C), 114.4 (CH x 2), 118.8 (CH), 123.5 (C), 124.6 (C), 126.6 (CH), 128.0 (CH), 130.2 (CH x 2), 143.9 (C), 150.1 (C), 152.8 (C), 155.9 (C), 160.8 (C), 165.3 (C), 172.5 (C); EIMS m/z 652 (M⁺, 63), 608 (43), 512 (21), 415 (30), 360 (38), 173 (100); HREIMS 652.2616 (calcd. for $C_{37}H_{39}O_7F_3$ (M⁺) 652.2648). 11-chloro-6-(4-methoxyphenyl)-3-methyl-7,12b-dihydro-1H-pyrano[3',2':5,6]pyrano[3,4c]chromen-1-one (17a) and 11-chloro-6-(4-methoxyphenyl)-3-methyl-7,12b-dihydro-1H-pyrano[3',4':5,6]pyrano[3,4-c]chromen-1-one (17b). 12 mg (0.07 mmol) of 2-methy-4-hydroxypirone, 30 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were dissolved in 2 mL of DCE. The reaction mixture was irradiated in a sealed tube at 120°C for 10 min. The solvent was removed under vacuum and compound 17a (19.1 mg, 45%) and 17b (20.5 mg, 45%) were obtained as with solids after purification by preparative-TLC with 40% Hex/EtOAc.

17a: Mp: 230.1-232.1 °C; IR (neat) v_{max} 3522, 3402, 1693, 1666, 1601, 1477, 1427, 1246, 1169, 1076, 957, 833, 663 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.31 (s, 1H), 3.84 (s, 3H), 4.83 (d, *J*=12.4 Hz, 1H), 4.87 (d, *J*= 12.4 Hz, 1H), 4.94 (s, 1H), 6.23 (s, 1H),

6.72 (d, J=8.7 Hz, 1H), 6.94 (d, J=8.5 Hz, 2H), 6.97 (s, 1H), 7.07 (d, J=8.5 Hz, 1H), 7.32 (d, J=8.4 Hz, 2H); ¹³C-NMR (125 MHz, CDCl₃) δ 19.2 (CH₃), 32.1 (CH), 55.4 (CH₃), 67.5 (CH₂), 97.3 (C), 107.9 (C), 113.7 (CH), 113.9 (CH x 2), 118.3 (CH), 123.3 (C), 125.9 (C), 126.2 (CH), 128.0 (CH), 129.1 (C), 129.9 (CH x 2), 144.3 (C), 152.4 (C), 160.8 (C), 161.3 (C), 161.7 (C), 179.9 (C); EIMS *m/z* 408 (M⁺, 100), 392 (25), 376 (22), 322 (23), 294 (24); HREIMS: 408.0776 (calcd. for C₂₃H₁₇O₅³⁵Cl 408.0765), 410.0754 (calcd. for C₂₃H₁₇O₅³⁷Cl 410.0754).

17b: Mp: 260.4-261.4 °C; IR (neat) v_{max} 3525, 3402, 2839, 1709, 1651, 1589, 1512, 1416, 1300, 1288, 1250, 1238, 1034, 968, 930, 818, 663 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 2.31 (s, 1H), 3.84 (s, 3H), 4.75 (s, 1H), 4.82 (d, *J*=12.4 Hz, 1H), 4.86 (d, *J*=12.4 Hz, 1H), 5.92 (s, 1H), 6.73 (d, *J*=8.2 Hz, 1H), 6.94 (d, *J*= 8.8 Hz, 2H), 7.07 (m, 2H), 7.29 (d, *J*=8.8 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 20.0 (CH₃), 31.1 (CH), 55.4 (CH₃), 67.8 (CH₂), 96.3 (C), 99.1 (CH), 107.0 (C), 113.9 (CH x 2), 118.4 (CH), 124.0 (C), 125.6 (CH), 125.9 (C), 127.9 (CH), 129.4 (C), 129.8 (CH x 2), 144.5 (C), 152.5 (C), 160.7 (C), 162.2 (C), 162.6 (C), 164.6 (C); EIMS *m/z* 408 (M⁺, 100), 392 (20), 376 (19), 322 (15), 294 (18); HREIMS: 408.0777 (calcd. for C₂₃H₁₇O₅³⁵Cl 408.0765), 410.0754 (calcd. for C₂₃H₁₇O₅³⁷Cl 410.0754).

2-chloro-7-(4-methoxyphenyl)-6H-pyrano[2,3-b:5,4-c']dichromen-14(14bH)-one (18a) and 5-chloro-14-(4-methoxyphenyl)-1H-pyrano[3,2-c:5,4-c']dichromen-7(6bH)-one (18b). 14 mg (0.07 mmol) of 4-hydroxycumarin, 30 mg (0.1 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 1.2 mg of EDDA (10 mol %) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120°C for 10 min. The solvent was removed under vacuum and compound 18a (13.6 mg, 37 %) and 18b (21.6 mg, 56 %) were obtained as white solids after purification by preparative-TLC with 1% toluene/acetone. **18a**: Mp: 290.6-292.1 °C; IR (neat) v_{max} 1709, 1612, 1570, 1477, 1423, 1242, 1053, 987, 975, 813, 756, 713, 682 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.86 (s, 3H), 4.88 (d, *J*=12.4 Hz, 1H), 4.95 (d, *J*=12.4 Hz, 1H), 5.10 (s, 1H), 6.75 (d, *J*=8.4 Hz, 1H), 6.95 (s, 1H), 6.97 (d, *J*= 8.8 Hz, 2H), 7.07 (dd, *J*=1.2, 8.4 Hz, 1H), 7.37 (d, *J*=8.9 Hz, 2H), 7.47 (m, 2H), 7.71 (t, *J*=7.3 Hz, 1H), 8.32 (d, *J*=7.4, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 32.5 (CH), 55.4 (CH₃), 67.5 (CH₂), 94.7 (C), 108.3 (C), 114.0 (2 x CH), 117.4 (CH), 118.3 (CH), 123.2 (C), 123.3 (C), 125.7 (CH), 125.9 (C), 126.1 (CH), 126.3 (CH), 128.0 (CH), 129.4 (C), 129.9 (CH x 2), 133.8 (CH), 144.2 (C), 152.4 (C), 153.1 (C), 160.9 (C), 161.6 (C), 178.1 (C); EIMS *m/z* 444 ([M⁺], 100), 429 (30), 413 (43), 324 (21), 295 (2); HREIMS 446.0766 (calcd. for C₂₆H₁₇O₅³⁷Cl (M⁺) 446.0735), 444.0753 (calcd. for C₂₆H₁₇O₅³⁵Cl (M⁺) 444.0765).

18b: Mp: 293.8-295.1°C; IR (neat) v_{max} 1712, 1608, 1512, 1477, 1377, 1288, 1049, 995, 941, 814, 652 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.87 (s, 3H), 4.89 (d, *J*=12.1 Hz, 1H), 4.90 (s, 1H), 4.95 (d, *J*=12.5 Hz, 1H), 6.76 (d, *J*=8.6 Hz, 1H), 6.99 (d, *J*=8.6 Hz, 2H), 7.04 (s, 1H), 7.08 (dd, *J*=1.7, 8.6 Hz, 1H), 7.32 (t, *J*=7.7 Hz, 1H), 7.41 (d, *J*=8.7 Hz, 2H), 7.44 (d, *J*=8.2 Hz, 1H), 7.62 (t, *J*=7.7, 1H), 7.81 (d, *J*= 7.9 Hz, 1H), 7.81 (d, *J*=7.5 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 31.7 (CH), 55.4 (CH₃), 67.9 (CH₂), 98.8 (C), 107.1 (C), 109.8 (C), 114.0 (CH x 2), 116.9 (CH), 118.6 (CH), 123.0 (CH), 124.0 (C), 124.4 (CH), 125.4 (CH), 126.0 (C), 128.0 (CH), 129.3 (C), 129.8 (2 x CH), 132.7 (CH), 144.4 (C), 152.5 (C), 153.0 (C), 157.7 (C), 160.8 (C), 162.8 (C); EIMS *m*/*z* 444 (M⁺, 100), 429 (28), 413 (41), 324 (20), 295 (13); HREIMS 446.0721 (calcd. for C₂₆H₁₇O₅³⁷Cl 446.0735), 444.0791 (calcd. for C₂₆H₁₇O₅³⁵Cl 444.0765). 2-chloro-7-(4-methoxyphenyl)benzo[*J*]chromeno[3,4-c]chromene-7,8(1H,6bH)-dione (**19a**) and 5-chloro-14-(4-methoxyphenyl)benzo[*h*]chromeno[3,4-c]chromene-7,8(1H,6bH)-dione (**19b**). 7.72 mg (0.044 mmol) of 2-hydroxy-1,4-naphtoquinone, 20

mg (0.07 mmol) of 5-chloro-2-(prop-2-yn-1-yloxy)benzaldehyde and 1 mg of EDDA (10 mol %) were dissolved in 2 mL of DCE. The reaction mixture was irradiated at 120°C for 10 min. The solvent was removed under vacuum and compound **19a** (11.1 mg, 55 %) and **19b** (6.1 mg, 31%) were obtained as white solids after purification by preparative-TLC with 1% DCM/MeOH.

19a: Mp: 164.2-165.8 °C; IR v_{max} 1680, 1642, 1548, 1258, 1352, 1172, 1076, 1022, 965, 825, 725 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.84 (s, 1H), 4.90 (d, J=12.4 Hz, 1H), 4.95 (d, J=12.8 Hz, 1H), 5.02 (s, 1H), 6.66 (d, J=1.4 Hz, 1H), 6.77 (d, J=8.6 Hz, 1H), 6.95 (d, J=8.8 Hz, 2H), 7.08 (dd, J=2.3, 8.7 Hz, 1H), 7.38 (d, J=8.6 Hz, 2H), 7.79 (td, J=1.2, 7.7 Hz, 1H), 7.83 (td, J=1.0, 7.4 Hz, 1H), 8.18 (d, J=7.7 Hz, 1H), 8.24 (d, J=7.6 Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 31.3 (CH), 55.4 (CH₃), 67.9 (CH₂), 106.5 (C), 113.9 (2 x CH), 117.4 (C), 118.8 (CH), 123.8 (C), 125.3 (CH), 125.8 (C), 126.7 (CH x 2), 128.0 (CH), 129.5 (C), 129.9 (2 x CH), 130.8 (C), 131.6 (C), 133.9 (CH), 134.6 (CH), 144.9 (C), 152.5 (C), 152.6 (C), 160.7 (C), 177.9 (C), 184.8 (C); EIMS *m/z* 456 (M⁺, 100), 384 (19), 282 (40), 252 (30), 135 (77); HREIMS 458.0738 (calcd. for $C_{27}H_{17}O_5^{37}Cl 458.0735$), 456.0771 (calcd. for $C_{27}H_{17}O_5^{35}Cl 456.0765$). **19b:** 122.8-124.0 °C; IR v_{max} 1674, 1605, 1512, 1477, 1300, 1250, 1177, 1076, 1026, 983, 818, 717, 671 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃) δ 3.87 (s, 1H), 4.90 (d, *J*=12.6 Hz, 1H), 4.92 (s, 1H), 4.95 (d, J=12.4 Hz, 1H), 6.72 (d, J=1.8 Hz, 1H), 6.75 (d, J=8.6 Hz, 1H), 7.00 (d, J=8.5 Hz, 2H), 7.07 (dd, J=2.3, 8.7 Hz, 1H), 7.40 (d, J=8.8 Hz, 2H), 7.64 (t, J=7.4 Hz, 1H), 7.71 (t, J=7.7 Hz, 1H), 7.87 (d, J=7.8 Hz, 1H), 8.23 (d, J=7.5

Hz, 1H); ¹³C-NMR (125 MHz, CDCl₃) δ 30.9 (CH), 55.5 (CH₃), 67.6 (CH₂), 108.2 (C), 110.8 (C), 113.6 (C), 114.6 (CH x 2), 118.6 (CH), 123.8 (C), 124.9 (CH), 125.6 (CH), 126.0 (C), 128.1 (CH), 129.6 (CH), 129.8 (CH x 2), 131.1 (C), 131.9 (CH), 133.3 (C), 135.3 (CH), 144.4 (C), 152.6 (C), 160.2 (C), 160.8 (C), 178.2 (C), 179.8 (C); EIMS *m/z* 456 (M⁺, 9), 437 (35), 334 (11), 152 (43), 135 (100); HREIMS 458.0750 (calcd. for $C_{27}H_{17}O_5^{37}Cl$ 458.0735), 456.0748 (calcd. for $C_{27}H_{17}O_5^{35}Cl$ 456.0765).

ASSOCIATED CONTENT

Supporting Information.

¹H and ¹³C NMR spectra of compounds **6a-6ai** and **7a-7ai**. HMBC spectrum of

compound 7a. This material is available free of charge via the Internet at

http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel.: 34 922318576. Fax: 34 922 318571. Email: aestebra@ull.es

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

We gratefully acknowledge the financial support from the Spanish MINECO SAF

2015-65113-C2-1-R to A.E.B. This project is also co-funded by the European Regional

Development Fund (FEDER). GF and AT are grateful to CICITCA-UNSJ and

CONICET, Argentina. PMA thanks to ACIISI for a predoctoral grant.

References

1-Harvey, A.L. Drug Discov. Today, 2008, 13, 894-900.

2- Patridge, E.; Gareiss, P.; Kinch, M.S.; Hoyer, D. Drug Discov. Today, 2016, 21,

204-207.

3-(a) Thomson, S.D. Naturally Occurring Quinones IV: Recent Advances, 1997,

Chapman&Hall, Thomson Press (India). (b) Ravelo, A.G.; Estévez-Braun, A.; Chávez-

The Journal of Organic Chemistry

2
3
4
4
5
6
7
6
ð
9
10
11
10
12
13
14
15
16
17
17
$\begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 3 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 23 \\ 34 \\ 35 \\ 36 \\ 7 \\ 8 \\ 9 \\ 40 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$
19
20
21
<u>2</u> 1
22
23
24
25
20
26
27
28
29
20
30
31
32
33
24
34
35
36
37
30
00
39
40
41
42
43
43
44
45
46
47
48
49
50
51
53
54
55
56
50
57
58
59
60
<u> </u>

Orellana, H.; Pérez-Sacau, E.; Mesa-Siverio, D. Curr. Topics. Med. Chem. 2004, 4, 241-265. 4-(a) Tapia-Juárez, M; J. González-Campos, B.; Contreras-Celedón, C.; Corona, D.; Cuevas-Yañez, E.; Chacón-García, L. RSC Adv., 2014, 4, 5660-5665. (b) Kitson, R.R.A.; Chang, C-H.; Xiong, R.; Williams, H. E.L.; Davis, A.L.; Lewis, W.; Dehn, D.L.; Siegel, D.; Mark Roe, S.; Prodromou, C.; Ross, D.; Moody, C.J. Nature *Chemistry* **2013**, *5*, 307-314. (c) Hong, Y.; Sengupta, S.; Hur, W.; Sim, T.J. Med. Chem. 2015, 58, 3739-3750. (d) Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. Angew. Chem. Int. Ed. 2002, 41, 1174-1178. (e) Stahl, P.; Kissau, L.; Mazitschek, R.; Huwe, A.; Furet, P.; Giannis, A.; Waldmann, H.; J. Am. Chem. Soc. 2001, 123, 11586-11593. (f) Jiménez-Alonso, S.; Chavez, H.; Estévez-Braun, A.; Ravelo, A.G.; Feresin, G.; Tapia, A. Tetrahedron 2008, 64, 8938-8942. (g) Jiménez-Alonso, S.; Pérez-Lomas, A.L.; Chavez, H.; Estévez-Braun, A.; Ravelo, A.G.; Gamarro, F.; Castanys, S.; Lopez, M. J. Med. Chem. 2008, 51, 7132-7143. 5- Feresin, G. E.; Tapia, A.; Sortino, M.; Zacchino, S.; de Arias, A.R.; Inchausti, A.; Yaluff, J.; Rodriguez, G.; Theoduloz, C.; Schmeda-Hirschmann G. J. Ethnopharmacol. 2003, 88, 241-247. 6- Gupta, G.; Kazmi, I.; Afzal, Muhammad; Upadhyay, Gaurav; Singh, Rajnish; Habtemariam, Solomon. *Phytopharmacology* **2013**, *4*, 87-95. 7- Nigam, N.; Grover, A.; Goyal, S.; Katiyar, S. P.; Bhargava, P.; Wang, P-C.; Sundar,

D.; Kaul, S.C.; Wadhwa, R. *PLoS One* **2015**, 10, e0138192/1-e0138192/15.

8- (a) Dhanjal, J.K.; Nigam, N.; Sharma, S.; Chaudhary, A.; Kaul, S. C.; Grover, A.;
Wadhwa, R. *BMC Cancer* 2014, *14*, 775/1-775/12. (b) Zhi-Gang, H.; Zhong-Zhi, T.;
Wen-Kai, Z.; Jian-Guo, L. *Inflammation* 2015, *38*, 527-533.

9- Mahendran, S.; Badami, S.; Ravi, S.; Thippeswamy, B. S.; Veerapur, V. P. British J. Pharm. Res. **2014**, *4*, 2182-2199.

10- Gupta, R.; Sharma, A. K.; Sharma, M. C.; Gupta, R. S. J. Diabetes 2012, 4, 248-256.

11- Naik, S. R.; Niture, N. T.; Ansari, A. A.; Shah, P.D., *Phytomedicine* **2013**, *20*, 797-804.

12- Deshmukh, P.T.; Gupta, V. B. J. Asian Nat. Prod. Res. 2013, 15, 158-165.

13- (a) Ravelo, A.G.; Estevez-Braun, A.; Jiménez Alonso, S.; Peña, R.; Machín, F.;
Mendez-Alvarez, S. Spanish Patent 2013, ES 2409536 A1 20130626. (b) Pena, R.;
Jimenez-Alonso, S.; Feresin, G.; Tapia, A.; Mendez-Alvarez, S.; Machin, F.; Ravelo, A.
G.; Estevez-Braun, A. J. Org. Chem. 2013, 78, 7977-7985. (c) Radhakrishnan, N.;
Gnanamani, A.; Mandal, A.B. *Biol. Medicine* 2011, 3, 1-7.

14- Senger, M.R.; Fraga, C.A.M.; Dantas, R.F.; Silva, F.P. *Drug Discov. Today*, **2016**, 1359-6446.

15- Filosa, R.; Peduto, A.; Schaible, A.M.; Krauth, V.; Weinigel, C.; Barz, D.; Petronzi,

C.; Bruno, F.; Roviezzo, F.; Spaziano, G.; D'Agostino, B.; De Rosa, M.; Werz, O. *Eur. J. Med. Chemistry* **2015**, *94*, 132-139.

16-Nigam, N.; Grover, A.; Goyal, S.; Katiyar, S.P.; Bhargava, P.; Wang, P-C.; Sundar,

D.; Kaul, S. C.; Wadhw. R. PLoS One 2015, 10, e0138192.

17- Hu, Rong; Zhu, Ke; Li, Yingchun; Yao, Kun; Zhang, Rong; Wang, Huihan; Yang,Wei; Liu, Zhuogang, *Medical Oncology* 2011, *28*, 1584-1588.

18- Wang, Da-Guang; Sun, Ya-Bin; Ye, Fei; Li, Wei; Kharbuja, Punyaram; Gao, Ling; Zhang, David Y.; Suo, Jian. *Mol. Cell. Biochemistry* **2014**, *386*, 143-152.

19- (a) Heo, J-Y.; Kim, H-J.; Kim, S-M.; Park, K-R.; Park, S-Y.; Kim, S-W; Nam, D-

W.; Jang, H-J.; Lee, S-G.; Ahn, K.-S. Cancer Lett. 2011, 308, 71-80. (b) Avisetti, D.R.;

Babu, K. S.; Kalivendi, S. V. PLoS One 2014, 9, e87050/1-e87050/10.

2
3
1
4
5
6
7
۵.
0
9
10
11
12
12
13
14
15
16
17
10
10
19
20
21
22
$\begin{array}{c} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 3 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 12 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 6 \\ 37 \\ 8 \\ 39 \\ 10 \\ 11 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 6 \\ 37 \\ 8 \\ 39 \\ 10 \\ 11 \\ 20 \\ 12 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 13 \\ 23 \\ 34 \\ 35 \\ 6 \\ 37 \\ 8 \\ 39 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 1$
23
24
25
26
27
21
28
29
30
31
00
32
33
34
35
26
30
37
38
39
40
10
41
42
43
44
45
40
46
46 47
48
49
50
51
52
53
51
54 55
55
56
57
58
59
59
60

20- Park, N.; Seok, B.H.; Chun, Y-J. PLoS One 2015, 10, e0134760/1-e0134760/17.

21-Schaible, A.M.; Traber, H.; Temml, V.; Noha, S.M.; Filosa, R.; Peduto, A.;

Weinigel, C.; Barz, D.; Schuster, D.; Werz, O. Bioch. Pharmacol. 2013, 86, 476-486.

- 22- Clemonsa, P.A.; Bodycombea, N.E.; Carrinskia, H.A.; Wilsona, J.A.; Shamjia,
- A.F.; Wagnera, B.K.; Koehlera, A.N.; Schreiber, S.L. PNAS 2010, 107, 18787-18790.

23- (a) Tarcsay, A.; Keseru, G.M. J.Med.Chem. 2013, 56, 1789-1795. (b) Yongye,

A.B.; Medina-Franco, J.L. J. Chem. Inform. Mod. 2012, 52, 2454-2461.

24-(a) Tietze L. F. Domino Reactions: Concepts for Efficient Organic Synthesis; WileyVCH: Weinheim, 2014. (b) Tietze, L.F.; Düfert A. Modern Tools for the Synthesis of *Complex Bioactive Molecules*; Wiley: Hoboken, NJ, 2012. (c) Tietze, L. F.; Brasche,
G.; Gericke, K. M. Domino Reactions in Organic Synthesis; Wiley VCH: Weinheim,
2006.

25- (a) Jiménez-Alonso, S.; Pérez-Lomas, A. L.; Estévez-Braun, A.; Muñoz-Martinez,

F.; Chávez-Orellana, H.; Ravelo, A. G.; Gamarro, F.; Castanys, S. López, M. J. Med.

Chem. 2008, 51, 7132-7143. (b) Jiménez-Alonso, S.; Chávez-Orellana, H.; Estévez-

Braun, A.; Ravelo, A. G.; Pérez-Sacau, E.; Machín, F. J. Med. Chem. 2008, 51, 6761-

6772. (c) Pena, R.; Martin, P.; Feresin, G.E.; Tapia, A.; Machin, F.; Estevez-Braun, A.

J. Nat. Prod. **2016**, *79*, 970-977. (d) McNaughton Smith, G.; Estevez Braun, A.; Jimenez Alonso, S.; Gutierrez Ravelo, A.; Fernandez-Perez, L.; Diaz Chico, Bonifacio Nicolas PCT Int. Appl. (2014), WO 2014016314 A1 20140130.

26-(a) Yamamoto, Y. J. Org. Chem, 2007, 72, 7817-7831 and references cited therein.

(b) Gouverneur, V.; Reiter, M. Chem. Eur. J. 2005, 11, 5806-5815

27-(a) Khoshkholgh, M.J.; Balalaie, S.; Bijanzadeh, H.R.; Gross, J. H.

Arkivoc, 2009, ix, 114-121. (b) Mollazadeh, M.; Khoshkholgh, M.J.; Balalaie, S.;

Rominger, F.; Bijanzadeh, H. R. J. Heterocycl. Chem. 2010, 47,1200-1208. (c)

Khoshkholgh, M.J.; Lofti, M.; Balalaie, S.; Rominger, F. *Tetrahedron* **2009**, *65*, 4228-4234.

28-Balalaie, S.; Azizian, J.; Shameli, A; Bijanzadeh, H. R. J. Iran. Chem. Soc. 2015, 12, 631-637.

- 29- Balalaie, S.; Poursaeed, A.; Malihe, J. K.; Bijanzadeh, H. R.; Wolf, E. *C.R. Chimie*, **2012**, *15*, 283-289.
- 30- Parmar, N.J.; Pansuriya, B.R.; Labana, B.M.; Sutariya, T.R.; Kant, R.; Gupta V. K. *Eur. J. Org. Chem* **2012**, 5953-5964.
- 31-Biswas, P.; Ghosh, J.; Bandyopadhyay, C. Tetrahedron Lett. 2014, 55, 6882-6886.
- 32-Sutariya, T.R.; Labana, B.M.; Parmar, B.D.; Parmar, N.J.; Kantb, R.; Gupta, V.K. *RSC Adv.*, **2015**, *5*, 23519-23529.
- 33-Majumdar, K. C.; Abu, T.; Kumar, N.R. Tetrahedron 2012, 68, 5693-5718.
- 34-(a) Biju, A. T.; Wurz, N. E.; Glorius, F. J. Am. Chem. Soc. 2010, 132, 5970-5971.
- (b) Perez-Serrano, L.; Blanco-Urgoiti, J.; Casarrubios, L.; Dominguez, G.; Perez-Castells, J. J. Org. Chem. 2000, 65, 3513-3519.
- 35-Hu, F.; Xia, Y.; Ma, C.; Zhang, Y.; Wang, J. J. Org. Chem. 2016, 81, 3275-3285.
- 36-Perrin, D. D.; Amarego, W. L. F. Purification of Laboratory Chemicals, 3rd ed.; Pergamon Press: Oxford, 1988.
- 37-Biju, A.T.; Wurz, N.E.; Glorius, F. J.A.C.S 2010, 132, 5970-5971.
- 38-Gai, R.; Prochnow, T.; Back, D. F.; Zeni, G. Tetrahedron 2014, 70, 3751-3756.
- 39-Rhee, J.U.; Krishe, M. J. Org. Lett. 2005, 7, 2493-2495.